var title_f22_58_23456="Tracheal anatomy";
var content_f22_58_23456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Anatomy of the trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23456=[""].join("\n");
var outline_f22_58_23456=null;
var title_f22_58_23457="Prone knee-chest position";
var content_f22_58_23457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Three-year-old girl in the prone knee-chest position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To allow visualization of the vaginal vault, the child should separate her knees and relax her abdominal muscles, and an assistant should retract the child's buttocks and labia majora. An otoscope head is a simple means of magnification and illumination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jan E Paradise, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23457=[""].join("\n");
var outline_f22_58_23457=null;
var title_f22_58_23458="CRPS child hand";
var content_f22_58_23458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Complex regional pain syndrome of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: David D Sherry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23458=[""].join("\n");
var outline_f22_58_23458=null;
var title_f22_58_23459="Betaine: Pediatric drug information";
var content_f22_58_23459=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Betaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41747?source=see_link\">",
"    see \"Betaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/26/7588?source=see_link\">",
"    see \"Betaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cystadane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cystadane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Homocystinuria, Treatment Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13207398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: PNA &ge;24 days (PMA not specified): 100 mg/kg/day divided into 2 doses; increase at weekly intervals in 50 mg/kg/day increments; minimal benefit has been shown in patients treated with &gt;150 mg/kg/day or exceeding a twice daily dosing schedule",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41747?source=see_link\">",
"      see \"Betaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Minimal benefit has been seen with dosages  &gt;150 mg/kg/day or &gt;20 g/day or exceeding a twice daily dosing schedule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &lt;3 years: 100 mg/kg/day divided into 2 doses; increase at weekly intervals in 50 mg/kg/day increments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;3 years, Adolescents, and Adults: 3 g twice daily; doses up to 20 g/day have been needed to control homocysteine plasma concentrations in some patients",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral, as anhydrous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cystadane&reg;: 1 g/scoop (180 g) [1 scoop = 1.7 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11239625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cystadane&reg; may be obtained by contacting Accredo Health Group Inc at 1-888-454-8860.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Shake bottle lightly before opening; measure prescribed amount with provided measuring scoop and dissolve in 4-6 ounces of water, juice, milk, or formula; may also mix with food; administer immediately; do not use if powder does not completely dissolve or gives a colored solution",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F4297921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from moisture",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of homocystinuria to reduce elevated homocysteine blood concentrations (FDA approved in ages 24 days to 17 years and adults); homocystinuria includes deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Betaine may be confused with Betadine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cystadane&reg; may be confused with cysteamine, cysteine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F140603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, dysgeusia, GI distress, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Alopecia, anorexia, agitation, cerebral edema (associated with hypermethioninemia), dental disorders, depression, hives, glossitis, irritability, personality disorder, sleep disturbances, skin odor abnormalities, urinary incontinence, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to betaine or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4297920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cerebral edema has been reported in patients with hypermethioninemia, including a few patients treated with betaine. Treatment of CBS with betaine may further increase methionine serum concentrations (due to remethylation of homocysteine to methionine); monitor methionine serum concentrations in patients with CBS deficiency; maintain methionine concentrations &lt;1,000 micromol/L. Therapy should be directed by a physician with expertise managing homocystinuria patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F140587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with betaine. It is not known whether betaine can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Betaine should be given to a pregnant woman only if needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma homocysteine concentration (should be low or undetectable); plasma methionine (CBS patients)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Betaine reduces homocysteine blood concentrations by acting as a methyl group donor in the remethylation of homocysteine to methionine",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin B",
"     <sub>",
"      6",
"     </sub>",
"     , vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     , and folate have been helpful in the management of homocystinuria and are often used in conjunction.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burns SP, Iles RA, Ryalls M, et al &ldquo;Methylgenesis From Betaine in Cystathionine-Beta-Synthase Deficiency,&rdquo;",
"      <i>",
"       Biochem Soc Trans",
"      </i>",
"      , 1993, 21:455S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23459/abstract-text/ 7510653 /pubmed\" id=\" 7510653 \" target=\"_blank\">",
"        7510653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Devlin AM, Hajipour L, Gholkar A, &ldquo;Cerebral Edema Associated With Betaine Treatment in Classical Homocystinuria,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001,144(4):545-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kishi T, Kawamura I, Harada Y, et al, &ldquo;Effect of Betaine on S-Adenosylmethionine Levels in the Cerebrospinal Fluid in a Patient With Methylenetetrahydrofolate Reductase Deficiency and Peripheral Neuropathy,&rdquo;",
"      <i>",
"       J Inherit Metab Dis",
"      </i>",
"      , 1994, 17(5):560-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23459/abstract-text/7837762/pubmed\" id=\"7837762\" target=\"_blank\">",
"        7837762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawson-Yuen A and Levy, HL, &ldquo;The Use of Betaine in the Treatment of Elevated Homocysteine,&rdquo;",
"      <i>",
"       Mol Genet Metab",
"      </i>",
"      , 2006, 88(3):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23459/abstract-text/16545978/pubmed\" id=\"16545978\" target=\"_blank\">",
"        16545978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matthews A, Johnson TN, Rostami-Hodjegan A, et al, &ldquo;An Indirect Response Model of Homocysteine Suppression by Betaine: Optimising the Dosage Regimen of Betaine in Homocystinuria,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2002, 54(2):140-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23459/abstract-text/ 12207633 /pubmed\" id=\" 12207633 \" target=\"_blank\">",
"        12207633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolin LA, Benevenga NJ, and Berlow S, &ldquo;The Use of Betaine for the Treatment of Homocystinuria,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1981, 99:467-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23459/abstract-text/7264811/pubmed\" id=\"7264811\" target=\"_blank\">",
"        7264811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13041 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-A7B55BFC08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23459=[""].join("\n");
var outline_f22_58_23459=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140590\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140591\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056826\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13207398\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056822\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140580\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140570\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11239625\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056829\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4297921\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056828\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140604\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140603\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056831\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4297920\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298857\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218393\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140577\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140587\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056825\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056821\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056832\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13041\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13041|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41747?source=related_link\">",
"      Betaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/26/7588?source=related_link\">",
"      Betaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_58_23460="Aztreonam: Patient drug information";
var content_f22_58_23460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aztreonam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     see \"Aztreonam: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1430?source=see_link\">",
"     see \"Aztreonam: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azactam&reg;;",
"     </li>",
"     <li>",
"      Cayston&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14942062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cayston&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aztreonam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad irritation where the shot was given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only as a liquid (solution) by a special machine (nebulizer) into the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a puffer (inhaler) that helps open your airways before using this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug after other breathed in drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator or at room temperature. If stored at room temperature, throw away any part not used after 28 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use right away after mixing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11297 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23460=[""].join("\n");
var outline_f22_58_23460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138579\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14942062\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026366\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026365\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026370\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026371\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026373\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026368\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026369\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026374\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026375\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=related_link\">",
"      Aztreonam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1430?source=related_link\">",
"      Aztreonam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_58_23461="External view of a direct inguinal hernia";
var content_f22_58_23461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    External view of a direct inguinal hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 608px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct inguinal hernias protrude through Hesselbach's triangle above the inguinal ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harwood-Nuss A, Wolfson AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23461=[""].join("\n");
var outline_f22_58_23461=null;
var title_f22_58_23462="Brain sites associated with cardiac troponin T elevation";
var content_f22_58_23462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Brain MRI map of cerebral infarction sites associated with cardiac troponin T (cTnT) elevation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A diffusion weighted MRI map of cerebral sites in patients with ischemic stroke highlights areas of infarction associated with cardiac troponin T (cTnT) elevation. The highlighted regions represent voxels linked to cTnT elevation with a p value of &lt;0.05 and include the right insula (posterior, superior, and medial regions) and the right inferior parietal lobe. The color bar indicates voxel-wise p values.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ay H, Koroshetz WJ, Benner T, et al. Neuroanatomic correlates of stroke-related myocardial injury. Neurology 2006; 66:1325. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23462=[""].join("\n");
var outline_f22_58_23462=null;
var title_f22_58_23463="Growth hormone treatment during the transition period";
var content_f22_58_23463=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth hormone treatment during the transition period",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/58/23463/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/58/23463/contributors\">",
"     Alan D Rogol, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/58/23463/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/58/23463/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/58/23463/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/58/23463/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/58/23463/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8327037\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of growth hormone deficiency (GHD) differ markedly depending on the life phase. During childhood and puberty, the most important effects of GH are on linear growth, and high doses of GH are required for replacement therapy. During adulthood, GHD is associated with altered body composition and diminished quality of life, and much lower GH doses are needed to counteract these effects. The diagnosis and management of these phases of GHD are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"     \"Treatment of growth hormone deficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link\">",
"     \"Growth hormone deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only a minority of children with GHD will remain deficient as adults and require ongoing GH therapy. The \"transition period\" between these phases is loosely defined as occurring from",
"    <strong>",
"    </strong>",
"    mid-to-late teens until six to seven years after reaching near-adult height. The transition period raises the following clinical questions, which will be addressed in this topic review:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Which individuals with childhood GHD will remain deficient as adults?",
"     </li>",
"     <li>",
"      When and how should testing be performed to determine whether an individual has persistent GHD?",
"     </li>",
"     <li>",
"      How should patients be monitored during and after the transition period to determine appropriate dosing for GH therapy?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These questions are not relevant to the disorders other than GHD for which GH treatment is indicated, including children born small for gestational age, chronic kidney disease, Turner syndrome, Prader-Willi syndrome (which may represent a GH-deficient state), and idiopathic short stature. For these disorders, GH therapy is generally stopped when linear growth is complete, with the possible exception of Prader-Willi syndrome, for which GH is sometimes continued into adulthood to enhance body composition, although this is still an experimental use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\", section on 'Growth hormone treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327044\">",
"    <span class=\"h1\">",
"     ANTICIPATORY GUIDANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Planning for management of GHD during the transition period should start at the initial diagnosis of GHD. In the past, most pediatric endocrinologists only planned to treat the child with GHD until near-adult height is reached (ie, growth less than 2.0 to 2.5 cm per year, which corresponds to the downward slope of height velocity after passing peak height velocity). However, individuals with persistent GHD benefit from continuing GH treatment into adulthood, because GH is required to achieve full adult body composition, regional distribution of body fat, and accrual of normal bone mineral content.",
"   </p>",
"   <p>",
"    Therefore, the following issues should be discussed in detail with the family",
"    <strong>",
"     before",
"    </strong>",
"    GH treatment is begun:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The child will require ongoing GH treatment during the transition period",
"     </li>",
"     <li>",
"      The child should be retested for GH deficiency during late adolescence (usually when they reach near-adult height)",
"     </li>",
"     <li>",
"      If the child remains GH-deficient when retested, he or she will be referred to an endocrinologist who evaluates and treats adults with GHD",
"     </li>",
"     <li>",
"      For individuals who remain GH-deficient during adulthood, lower doses of GH are required for treatment as compared with childhood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This discussion prepares the patient and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    parents for the retesting and possible referral to another endocrinologist, when the appropriate time arrives. The pediatric endocrinologist typically initiates the process for retesting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12213561\">",
"    <span class=\"h1\">",
"     PREDICTING RISK FOR CONTINUING GROWTH HORMONE DEFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327051\">",
"    <span class=\"h2\">",
"     Isolated GHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children with",
"    <strong>",
"     isolated",
"    </strong>",
"    GHD, more than two thirds will have normal results when retested for GHD during late adolescence or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/3\">",
"     3",
"    </a>",
"    ]. These discrepancies are probably in part because of the inherent imprecision in diagnosing GHD, because of the low reproducibility of the stimulation tests. In addition, a mild GHD may not have clinically important effects during adulthood because the metabolic effects of GH are seen at low doses, whereas the same individual may have clinically important effects during childhood because high concentrations of GH are required to stimulate growth.",
"   </p>",
"   <p>",
"    Because the majority of patients with isolated GHD will be GH sufficient by late adolescence or adulthood, it is important to repeat the GH stimulation test during the transition period to determine if they require ongoing therapy. (See",
"    <a class=\"local\" href=\"#H8327080\">",
"     'Testing for continuing growth hormone deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327058\">",
"    <span class=\"h2\">",
"     Genetic, organic, or structural causes of GHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;By contrast, GHD is usually permanent in virtually all patients with the following causes of GHD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Genetic",
"      </strong>",
"      GHD (either isolated or as part of a more complex pituitary hormone deficiency syndrome). Genetic GHD is usually recognized by the presence of affected relatives and confirmed by molecular testing for the causative genes, which include POU1F1 (Pit-1), PROP-1, and GH-1. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis of growth hormone deficiency in children\", section on 'Molecular genetics of growth hormone deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Structural causes",
"      </strong>",
"      (eg, associated with mid-line craniofacial anomalies such as optic nerve",
"      <span class=\"nowrap\">",
"       hypoplasia/septo-optic",
"      </span>",
"      dysplasia). GHD is highly likely to be permanent in patients with congenital anomalies in the sellar or suprasellar region, as shown by magnetic resonance imaging (MRI) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Organic causes",
"      </strong>",
"      of GHD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      GHD following brain surgery and radiation therapy for craniopharyngioma or other brain tumors.",
"     </li>",
"     <li>",
"      GHD following radiation therapy to the brain for hematologic malignancies (which is especially common with doses &gt;40 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Infants or young children are particularly vulnerable to developing permanent GHD after brain radiation; some also develop precocious puberty (especially girls).",
"     </li>",
"     <li>",
"      Multiple pituitary hormone deficiencies. As an example, for those with deficiencies of three or more pituitary hormones, the likelihood of persistent GHD is greater than 95 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because patients with these characteristics are very likely to have permanent GHD, extensive testing for GHD during the transition period is not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4\">",
"     4",
"    </a>",
"    ]. Instead, the ongoing deficiency can be confirmed by discontinuing GH therapy for approximately one month and then measuring the serum concentration of IGF-I. If the IGF-I concentration is below -2 SD from the mean, ongoing GHD is effectively confirmed. In the past, some insurance companies required more extensive GH stimulation testing, as described below. However, clinical practice guidelines specifically state that stimulation testing is NOT necessary to confirm permanent GHD in patients with these characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4\">",
"     4",
"    </a>",
"    ]. Note that a normal serum IGF-I in this context does not rule out GHD in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8327119\">",
"     'Tests to evaluate for continuing GHD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3638513\">",
"    <span class=\"h2\">",
"     Other predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have very low GH peaks during stimulation tests done as children (GH &lt;3",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    are more likely to have permanent GHD as compared with those with higher peak stimulated levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327080\">",
"    <span class=\"h1\">",
"     TESTING FOR CONTINUING GROWTH HORMONE DEFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327088\">",
"    <span class=\"h2\">",
"     When should retesting be done?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing for testing for continuing GHD during the transition period has not been established. Each of the following approaches has merit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retesting as near-adult height is reached (ie, when the growth rate decelerates to 2.0 to 2.5",
"      <span class=\"nowrap\">",
"       cm/year),",
"      </span>",
"      generally occurring in late puberty. This is the most commonly used approach.",
"     </li>",
"     <li>",
"      Retesting in mid-puberty. This approach is based on the hypothesis that entry into puberty stimulates the GH-secreting apparatus in those children who would eventually become GH sufficient [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/9\">",
"       9",
"      </a>",
"      ]. If the patient is no longer GH deficient, then testing at this time would reduce the length of GH treatment by three years or more. This approach is not optimal for patients with a high likelihood of having permanent GHD (eg, patients with multiple pituitary hormone deficiencies).",
"     </li>",
"     <li>",
"      Retesting at the end of the transition phase (age in mid-20s). Disadvantages of this approach are that patients without ongoing GHD would have several years of unnecessary treatment, and those with ongoing GHD would be treated for several years with the higher doses required for growth stimulation, rather than the lower dose required for metabolic effects in an adult. Therefore, this approach is not optimal for patients with isolated GHD, among whom the majority will not need ongoing GH treatment as adults.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who have a history of cranial radiation therapy, the results of retesting should not be considered definitive because radiation tends to cause progressive damage to the hypothalamus and pituitary. Even if GH testing is normal several years after completion of radiation therapy, the patient may still become increasingly growth hormone deficient. Therefore, patients should be retested for GHD for five to ten years after completion of radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327119\">",
"    <span class=\"h2\">",
"     Tests to evaluate for continuing GHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin tolerance test (ITT, or insulin-induced hypoglycemia test) remains widely regarded as the \"gold standard\" test for the diagnosis of adult GH deficiency. GH therapy should be stopped for at least one month prior to testing. In adult patients with multiple pituitary hormone deficiencies tested with ITT, a peak GH response of &lt;5.1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    has approximately 95 percent specificity and sensitivity for detecting GHD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. The cutoff values for adolescents may be slightly higher than those in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link&amp;anchor=H13#H13\">",
"     \"Growth hormone deficiency in adults\", section on 'Insulin-induced hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stimulation with the combination of arginine and growth hormone releasing hormone (GHRH) has similar sensitivity and specificity for detecting GHD in adults and is generally used instead of the ITT in countries in which GHRH is available because it avoids the risk of hypoglycemia. For this test, a peak GH response of &lt;19.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    has a sensitivity of approximately 100 percent and specificity of 97 percent for detecting GHD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/13\">",
"     13",
"    </a>",
"    ]. Stimulation with",
"    <span class=\"nowrap\">",
"     arginine/L-DOPA,",
"    </span>",
"    arginine alone, or L-DOPA has considerably inferior sensitivity and specificity for the diagnosis of GHD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In countries in which GHRH is not available, and the insulin-induced hypoglycemia test is contraindicated in a given patient (eg, patients with coronary or cerebrovascular disease or those at risk for seizures, such as patients who have had transcranial surgery for craniopharyngioma, etc.),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    (1 mg) can be used for a stimulation test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4\">",
"     4",
"    </a>",
"    ]. Sampling is continued for three or four hours because there are some late responders to this stimulus. Published reports indicate a sensitivity of 97 to 100 percent and a specificity of 88 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the evidence base for this test is much smaller than those for the ITT and",
"    <span class=\"nowrap\">",
"     arginine/GHRH",
"    </span>",
"    tests. A separate study reported that the glucagon test is considerably less sensitive than the ITT because 14 percent of the patients would have been misclassified by the glucagon stimulation test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For all of these stimulation tests, the optimal cutoff and predictive values results in lean individuals differ markedly from those who are obese. For example, for the",
"    <span class=\"nowrap\">",
"     GHRH/arginine",
"    </span>",
"    test, the highest pair of",
"    <span class=\"nowrap\">",
"     sensitivity/specificity",
"    </span>",
"    values for GH deficiency are 98.7 and 83.7 percent for a peak GH response &lt;11.5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in lean individuals (BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     );",
"    </span>",
"    96.7 and 75.5 percent at &lt;8.0",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in overweight individuals (25&lt;BMI&lt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    and 93.5 and 78.3 percent at &lt;4.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in obese individuals (BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, obese individuals without GHD have a blunted response to stimulation testing (lower peak value) as compared with lean individuals, and stimulation tests are somewhat less accurate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327134\">",
"    <span class=\"h2\">",
"     Decision to treat in individuals who remain GH deficient as adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stopping GH therapy during adolescence in a patient with ongoing GHD affects adult body composition. Muscle mass and bone mineral accrual are diminished and regional distribution of body fat is altered, with increased total body fat and a greater proportion in the deep visceral compartment, changes that are associated with increased cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4,17,18\">",
"     4,17,18",
"    </a>",
"    ]. The effects of GH on bone mineral density are particularly important during early adulthood, when bone mass normally continues to accumulate. In addition, adult GHD is associated with subjective symptoms, including diminished quality of life, especially energy and vitality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/19\">",
"     19",
"    </a>",
"    ]. Continued treatment with GH prevents most of these consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, for most patients with GHD during childhood who also have evidence of GHD when retested during the transition period, we suggest treatment with GH during adulthood. This will include most patients with underlying genetic, organic, or structural causes of GHD. By contrast, continued GH treatment in adulthood is not necessary for asymptomatic patients, particularly if the results of GH testing are equivocal. Furthermore, for those adults in whom GH treatment is initiated, or for whom no apparent or objective benefit of treatment can be gleaned after one year, we suggest stopping GH therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4\">",
"     4",
"    </a>",
"    ]. Treatment with GH is not recommended in patients with active malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link&amp;anchor=H3#H3\">",
"     \"Growth hormone deficiency in adults\", section on 'Clinical manifestations and benefits of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327149\">",
"    <span class=\"h2\">",
"     Dosing and monitoring GH therapy during the transition and into young adulthood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of GH required for growth during childhood and adolescence is higher in terms of absolute dose, and far higher per kilogram of body weight as compared with doses required to treat GHD during adulthood. The relatively high doses of GH are continued until linear growth is nearly complete (ie, the growth rate decelerates to 2.0 to 2.5",
"    <span class=\"nowrap\">",
"     cm/year).",
"    </span>",
"    A few adolescents with suboptimal growth on standard doses of GH are treated with \"pubertal dosing\" in the range of 70",
"    <span class=\"nowrap\">",
"     micrograms/kg",
"    </span>",
"    per day to mimic physiology and to maximize linear growth (as compared to the usual prepubertal dose of 40",
"    <span class=\"nowrap\">",
"     micrograms/kg/day).",
"    </span>",
"    Studies of long-term effects using these high pubertal doses of GH are lacking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After linear growth is complete the patient is transitioned to &ldquo;adult dosing&rdquo; if ongoing GH treatment is indicated. The starting dose for an adult is approximately 200 to 300 micrograms per day (total dose). Women will often require a larger dose than men (in the range of 600 to 900 micrograms per day and more if they are receiving oral estrogens).",
"   </p>",
"   <p>",
"    To optimize the GH dose for an adolescent during the transition period, we begin with the adult dose and then titrate to a serum IGF-I level in the upper portion of the normal range for age and gender. In our practice, we measure serum IGF-I concentrations one to two months after beginning the adult dose of GH and titrate the GH dose until the IGF-I level is within the appropriate range without side effects such as those related to fluid retention [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8327095\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Monitoring of therapy should follow the plan noted in the paragraph just above. When the appropriate dose is attained without side effects, the frequency of visits can decrease to one to two per year. At each visit the history is reviewed for possible treatment-emergent adverse events, IGF-I level, fasting glucose level, Hemoglobin A1c, and a lipid profile. Since GH affects body composition and the regional distribution of body fat, we also obtain a dual x-ray absorptiometry (DXA) scan for body composition and bone mineral density at the onset of therapy. If the initial results are abnormal, we repeat the scan periodically (eg, at least 18 months later) to objectively define the response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with GHD during childhood caused by radiation therapy should be followed with serial stimulation tests during adulthood, even if the test during the transition period suggested no residual GHD. This is because the damage to the hypothalamus and pituitary function caused by radiation may continue to progress over five to ten years after the end of the radiation therapy.",
"   </p>",
"   <p>",
"    A quality of life inventory may be helpful in patients with somatic and psychological complaints because reduced quality of life can be an indication for GH therapy in GH deficient adults. Quality of life is usually assessed via self-administered questionnaires that reflect a variety of health-related, economic, and social factors. Quality of life measures may be broadly correlated with, but are different from, assessments of affect or cognition. Disease-specific quality of life assessment questionnaires have been validated and are now widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4,22,23\">",
"     4,22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link&amp;anchor=H8#H8\">",
"     \"Growth hormone deficiency in adults\", section on 'Quality of life'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327095\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p>",
"    GH therapy of adults with GHD has generally been regarded as being quite safe. The following possible adverse effects should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concerns remain regarding the potential for cancer risk and tumor regrowth [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4,7,24\">",
"       4,7,24",
"      </a>",
"      ]. Therefore, GH therapy is not recommended for patients with active malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of growth hormone deficiency in children\", section on 'Adverse effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although GH treatment decreases insulin sensitivity, abnormal fasting glucose levels rarely occur.",
"     </li>",
"     <li>",
"      Since the thyroid and adrenal axes may be affected by GH therapy, it is prudent to periodically check for dysfunction by measuring free T4 (and not TSH) and an early morning cortisol concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/4,7\">",
"       4,7",
"      </a>",
"      ]. Patients with GHD due to radiation therapy are particularly at risk because they may experience progressive damage over time, affecting the thyroid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      adrenal axes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Growth hormone therapy may unmask preexisting central hypothyroidism, because GH increases the peripheral conversion of T",
"      <sub>",
"       4",
"      </sub>",
"      to T",
"      <sub>",
"       3",
"      </sub>",
"      . This abnormality is recognized by a fall of the serum free T",
"      <sub>",
"       4",
"      </sub>",
"      level into the subnormal range [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/7,25\">",
"       7,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Growth hormone therapy may unmask secondary adrenal insufficiency because GH reduces the activity of 11&beta;-hydroxysteroid dehydrogenase, type 1, the enzyme that converts inactive cortisone to cortisol. Similarly, in a patient with central adrenal failure, initiation of GH therapy may require an increase in the dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23463/abstract/7,26\">",
"       7,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other reported adverse effects of GH are peripheral edema, arthralgias, carpal tunnel syndrome, and paresthesias. However, these were mostly reported in patients with adult-onset GHD and were dose-related. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=see_link&amp;anchor=H22#H22\">",
"       \"Growth hormone deficiency in adults\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=see_link\">",
"       \"Patient information: My child is short (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8327111\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only a minority of children with growth hormone deficiency (GHD) will remain deficient as adults and require ongoing growth hormone (GH) therapy. The \"transition period\" between these phases is loosely defined as occurring from",
"      <strong>",
"      </strong>",
"      mid-to-late teens until six to seven years after reaching near-adult height.",
"     </li>",
"     <li>",
"      Among children with",
"      <strong>",
"       isolated",
"      </strong>",
"      GHD, more than two thirds will have normal results when tested for GHD as adults. Because the majority of these patients with isolated GHD during childhood will be GH-sufficient as adults, it is important to repeat the GH stimulation test during the transition period to determine if they will require ongoing therapy. (See",
"      <a class=\"local\" href=\"#H8327080\">",
"       'Testing for continuing growth hormone deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      By contrast, GHD is usually permanent in patients with",
"      <strong>",
"       genetic",
"      </strong>",
"      causes of GHD (recognized by a family history of GHD),",
"      <strong>",
"       structural",
"      </strong>",
"      causes of GHD (eg, optic nerve hypoplasia), or",
"      <strong>",
"       organic",
"      </strong>",
"      GHD (eg, caused by brain surgery, brain tumors, intracranial irradiation, or associated with multiple pituitary hormone deficiencies). (See",
"      <a class=\"local\" href=\"#H8327058\">",
"       'Genetic, organic, or structural causes of GHD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retesting for GHD during the transition period is usually done when near-adult height is reached (ie, when the growth rate decelerates to 2.0 to 2.5",
"      <span class=\"nowrap\">",
"       cm/year),",
"      </span>",
"      occurring in late puberty. Earlier retesting (eg, in mid-puberty) may be beneficial for patients with mild isolated GHD. Later retesting (eg, in young adulthood) can be considered for patients with a high risk for ongoing GHD (genetic, structural, or organic GHD). (See",
"      <a class=\"local\" href=\"#H8327088\">",
"       'When should retesting be done?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retesting for GHD during the transition period usually employs the insulin tolerance test (ITT), which induces hypoglycemia to stimulate growth hormone release. A peak GH response of &lt;5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      suggests GHD. The combination of arginine and growth hormone releasing hormone (GHRH) is an appropriate alternate choice in countries in which GHRH is available. (See",
"      <a class=\"local\" href=\"#H8327119\">",
"       'Tests to evaluate for continuing GHD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because patients with genetic, structural, or organic causes of GHD are very likely to have permanent GHD, repeat stimulation testing for GHD usually is not necessary. Instead, the ongoing deficiency can be confirmed by interrupting GH therapy during the transition period and documenting low serum concentration of IGF-I. (See",
"      <a class=\"local\" href=\"#H8327058\">",
"       'Genetic, organic, or structural causes of GHD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have a history of cranial radiation therapy, the results of retesting should not be considered definitive, because radiation tends to cause progressive damage to the hypothalamus and pituitary. Patients who are GH-sufficient during the transition period may develop increasing GHD over time and should be followed and retested for GHD periodically. (See",
"      <a class=\"local\" href=\"#H8327088\">",
"       'When should retesting be done?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with GHD during childhood who also have evidence of GHD when retested during the transition period, we suggest treatment with GH during adulthood (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, GH treatment in adulthood is not required for asymptomatic patients without underlying genetic, organic, or structural causes of GHD, particularly if the results of GH testing are equivocal. (See",
"      <a class=\"local\" href=\"#H8327134\">",
"       'Decision to treat in individuals who remain GH deficient as adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As compared with GH dosing for children, GH doses for adults are lower in terms of absolute dose, and far lower per kilogram of body weight. The starting dose for an adult is approximately 200 to 300 micrograms per day. Women will often require a larger dose. To optimize the GH dose for an adolescent during the transition period, we begin with the adult dose and then titrate to an IGF-I level in the upper portion of the normal range for age and gender. (See",
"      <a class=\"local\" href=\"#H8327149\">",
"       'Dosing and monitoring GH therapy during the transition and into young adulthood'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/1\">",
"      Clayton PE, Cuneo RC, Juul A, et al. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005; 152:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/2\">",
"      Sode-Carlsen R, Farholt S, Rabben KF, et al. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome. Growth Horm IGF Res 2011; 21:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/3\">",
"      Tauber M, Moulin P, Pienkowski C, et al. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 1997; 82:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/4\">",
"      Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/5\">",
"      Adan L, Trivin C, Sainte-Rose C, et al. GH deficiency caused by cranial irradiation during childhood: factors and markers in young adults. J Clin Endocrinol Metab 2001; 86:5245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/6\">",
"      Hartman ML, Crowe BJ, Biller BM, et al. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002; 87:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/7\">",
"      Ho KK, 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007; 157:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/8\">",
"      Secco A, di Iorgi N, Napoli F, et al. Reassessment of the growth hormone status in young adults with childhood-onset growth hormone deficiency: reappraisal of insulin tolerance testing. J Clin Endocrinol Metab 2009; 94:4195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/9\">",
"      Loche S, Bizzarri C, Maghnie M, et al. Results of early reevaluation of growth hormone secretion in short children with apparent growth hormone deficiency. J Pediatr 2002; 140:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/10\">",
"      Toogood AA, Beardwell CG, Shalet SM. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin Endocrinol (Oxf) 1994; 41:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/11\">",
"      Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/12\">",
"      Maghnie M, Aimaretti G, Bellone S, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol 2005; 152:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/13\">",
"      Corneli G, Di Somma C, Prodam F, et al. Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. Eur J Endocrinol 2007; 157:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/14\">",
"      Yuen KC, Biller BM, Molitch ME, Cook DM. Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency? J Clin Endocrinol Metab 2009; 94:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/15\">",
"      Berg C, Meinel T, Lahner H, et al. Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur J Endocrinol 2010; 162:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/16\">",
"      Corneli G, Di Somma C, Baldelli R, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 2005; 153:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/17\">",
"      Attanasio AF, Shavrikova E, Blum WF, et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab 2004; 89:4857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/18\">",
"      Maiter D, Abs R, Johannsson G, et al. Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database. Eur J Endocrinol 2006; 155:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/19\">",
"      Koltowska-H&auml;ggstr&ouml;m M, Mattsson AF, Shalet SM. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol 2009; 161 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/20\">",
"      Carroll PV, Drake WM, Maher KT, et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. J Clin Endocrinol Metab 2004; 89:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/21\">",
"      Kotowska-H&auml;ggstr&ouml;m M, Geffner ME, J&ouml;nsson P, et al. Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency. J Clin Endocrinol Metab 2010; 95:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/22\">",
"      Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 2004; 89:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/23\">",
"      McKenna SP, Doward LC, Alonso J, et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999; 8:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/24\">",
"      Svensson J, Bengtsson BA. Safety aspects of GH replacement. Eur J Endocrinol 2009; 161 Suppl 1:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/25\">",
"      Losa M, Scavini M, Gatti E, et al. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid 2008; 18:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23463/abstract/26\">",
"      Giavoli C, Lib&eacute; R, Corbetta S, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 2004; 89:5397.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16539 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23463=[""].join("\n");
var outline_f22_58_23463=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8327111\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8327037\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8327044\">",
"      ANTICIPATORY GUIDANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12213561\">",
"      PREDICTING RISK FOR CONTINUING GROWTH HORMONE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8327051\">",
"      Isolated GHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8327058\">",
"      Genetic, organic, or structural causes of GHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3638513\">",
"      Other predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8327080\">",
"      TESTING FOR CONTINUING GROWTH HORMONE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8327088\">",
"      When should retesting be done?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8327119\">",
"      Tests to evaluate for continuing GHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8327134\">",
"      Decision to treat in individuals who remain GH deficient as adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8327149\">",
"      Dosing and monitoring GH therapy during the transition and into young adulthood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8327095\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8327111\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1833?source=related_link\">",
"      Growth hormone deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/12/3266?source=related_link\">",
"      Patient information: My child is short (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_58_23464="Manifestations of hyponatremia and hypernatremia";
var content_f22_58_23464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Manifestations of hyponatremia and hypernatremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/58/23464/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/58/23464/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/58/23464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/58/23464/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/58/23464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/58/23464/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/58/23464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of hyponatremia or hypernatremia are primarily neurologic. They are related to the severity and, in particular, the rapidity of the change in the serum sodium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients with hyponatremia and hypernatremia may also have complaints related to concurrent volume depletion and possible underlying neurologic diseases that predispose to the electrolyte abnormality. These include a wide variety of neurologic disorders that can lead sequentially to either the inappropriate secretion of antidiuretic hormone, water retention, and hyponatremia, or to the lack of expression of thirst, which is normally the major protective mechanism against the development of hypernatremia.",
"   </p>",
"   <p>",
"    The cerebral adaptation and clinical manifestations of hyponatremia and hypernatremia will be reviewed here. The etiology and treatment of hyponatremia and hypernatremia are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link\">",
"     \"Treatment of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPONATREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms directly attributable to hyponatremia primarily occur with acute and marked reductions in the serum sodium concentration and reflect neurologic dysfunction induced by cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ], and possibly adaptive responses of brain cells to osmotic swelling. In this setting, the associated fall in serum osmolality creates an osmolal gradient that favors water movement into the cells, leading to brain edema.",
"   </p>",
"   <p>",
"    The development of cerebral edema in hyponatremic patients is dependent upon the transfer of water from plasma and cerebrospinal fluid into the brain. Insight into this process is provided by studies in mice without the genes for aquaporin-4, a water channel expressed at the interface between the brain and blood and between the brain and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/5\">",
"     5",
"    </a>",
"    ]. Compared with wild-type mice, knockout mice exhibit considerably less brain edema, morbidity, and mortality after the induction of acute hyponatremia, suggesting that aquaporin-4 mediates a substantial portion of osmotic water transport into the brain.",
"   </p>",
"   <p>",
"    Hyponatremia-induced cerebral edema occurs primarily with rapid reductions in the serum sodium concentration, usually less than 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/4\">",
"     4",
"    </a>",
"    ], as most often occurs in postoperative patients given large quantities of hypotonic fluid and in patients with self-induced water intoxication due to primary polydipsia or exercise-associated hyponatremia. Hypoxic brain injury also may contribute to the neurologic deficit if respiratory arrest has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=see_link\">",
"     \"Exercise-associated hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238335439\">",
"    <span class=\"h2\">",
"     Importance of hypoosmolality in symptom development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is almost always associated with hypoosmolality, and it is the fall in plasma osmolality that promotes the movement of water into the cells and the possible development of cerebral edema. The contribution of hyponatremia itself to the neurologic manifestations is uncertain. This is an important issue, since there are a variety of settings in which hyponatremia is associated with a normal or high measured serum osmolality. These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H16#H16\">",
"     \"Causes of hyponatremia\", section on 'Hyponatremia with a high or normal serum osmolality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In",
"      <strong>",
"       pseudohyponatremia",
"      </strong>",
"      , both the serum osmolality and the concentration of sodium in plasma water are normal, and patients are asymptomatic. Such patients have either hyperproteinemia or hyperlipidemia, which reduce the fraction of the plasma that is water from the normal value of 93 percent (the remaining 7 percent is due to proteins and lipids with a small contribution from dissolved solutes) to a lower value that can be less than 80 percent. In such settings, the physiologically important sodium concentration per liter of plasma water is normal, although the sodium concentration per liter of plasma is reduced. The plasma osmolality is normal because osmometers measure the activity of solutes in plasma water.",
"     </li>",
"     <li>",
"      With moderate to advanced",
"      <strong>",
"       renal impairment",
"      </strong>",
"      or with",
"      <strong>",
"       ethanol intoxication",
"      </strong>",
"      , hyponatremic patients may have a higher osmolality than that predicted by their sodium concentration due to the contribution of urea or ethanol in the extracellular fluid. However, urea and ethanol are ineffective osmoles since they can freely cross cell membranes and therefore do not obligate water movement out of the cells. Thus, the effective serum osmolality (measured osmolality minus the contribution of urea or ethanol) in such patients is low. As a result, hyponatremic patients with renal failure or ethanol intoxication are as likely to develop symptoms at a given serum sodium concentration as patients without these conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H13#H13\">",
"       \"Causes of hyponatremia\", section on 'Advanced renal failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with",
"      <strong>",
"       uncontrolled diabetes",
"      </strong>",
"      , the serum osmolality is typically elevated. In contrast to urea, glucose is an effective osmole since it does not freely enter cells. The increase in effective serum osmolality pulls water out of the cells and lowers the serum sodium by dilution, an effect that may be at least partially reversed by the free water loss resulting from the associated glucosuria-induced osmotic diuresis. The neurologic symptoms in these patients are",
"      <strong>",
"       not",
"      </strong>",
"      generated by the hyponatremia since the effective plasma osmolality is usually increased rather than reduced. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum sodium'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Neurologic symptoms and plasma osmolality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Isosmotic (or near isosmotic) non-sodium containing, nonconductive",
"      <strong>",
"       irrigation solutions",
"      </strong>",
"      containing glycine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      may be used during transurethral resection of the prostate or bladder, during hysteroscopy, or laparoscopic surgery. Only a small quantity of this solution is usually absorbed systemically. However, large amounts of the irrigant are occasionally infused by accident into veins or body cavities. Severe isosmotic hyponatremia due to dilution can result (serum sodium less than 110",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      which can produce neurologic symptoms. In addition to hyponatremia, glycine toxicity and the accumulation of ammonia, serine,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glyoxylate from the metabolism of glycine may contribute to neurologic manifestations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=see_link&amp;anchor=H16#H16\">",
"       \"Hyponatremia following transurethral resection or hysteroscopy\", section on 'Pathogenesis of neurologic symptoms'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations of acute hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of symptoms in patients with acute hyponatremia generally reflects the severity of cerebral overhydration, which is related to the degree of hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/1\">",
"     1",
"    </a>",
"    ]. The major clinical manifestations of acute hyponatremia include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/1,6-10\">",
"     1,6-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nausea and malaise, which are the earliest findings, may be seen when the serum sodium concentration falls below 125 to 130",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Headache, lethargy, obtundation and eventually seizures, coma, and respiratory arrest can occur if the serum sodium concentration falls below 115 to 120",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Noncardiogenic pulmonary edema has also been described.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute hyponatremic encephalopathy may be reversible, but permanent neurologic damage or death can occur, particularly in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Overly rapid correction also may be deleterious, particularly in patients with chronic hyponatremia. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Susceptibility of premenopausal women'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Osmotic demyelination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Osmolytes and cerebral adaptation to hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of cerebral edema and therefore the severity of neurologic symptoms are much less with chronic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/1,11,12\">",
"     1,11,12",
"    </a>",
"    ]. This protective response, which begins on the first day and is complete within several days, occurs in two major steps.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial cerebral edema raises the interstitial hydraulic pressure, creating a gradient for extracellular fluid movement out of the brain into the cerebrospinal fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The brain cells then lose solutes, leading to the osmotic movement of water out of the cells and a decrease in brain swelling [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/3,4,11,13-17\">",
"       3,4,11,13-17",
"      </a>",
"      ]. Brain cell potassium is lost rapidly through normally quiescent cation channels in the cell membrane that are activated by cell swelling. Subsequently, organic solutes (called organic osmolytes) are lost via swelling-activated membrane channels that also transport chloride and other anions [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/3,14\">",
"       3,14",
"      </a>",
"      ]. Substantial depletion of brain organic osmolytes occurs within 24 hours, and additional losses occur over two to three days owing to downregulation of the synthesis and uptake of these solutes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These processes are reversed with correction of the hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/3,4,17\">",
"     3,4,17",
"    </a>",
"    ]. However, the reuptake of brain solutes during correction occurs more slowly than the loss of brain solutes during the onset of hyponatremia.",
"   </p>",
"   <p>",
"    Organic osmolytes account for approximately one-third of the solute loss in chronic hyponatremia (",
"    <a class=\"graphic graphic_figure graphicRef71152 \" href=\"UTD.htm?26/22/26989\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/16\">",
"     16",
"    </a>",
"    ]. Reducing the intracellular content of these solutes has the advantage of restoring cell volume without interfering with protein function. In comparison, there would be a potentially deleterious effect on protein function if the volume adaptation were mediated entirely by changes in the cell cation (potassium plus sodium) concentration.",
"   </p>",
"   <p>",
"    Studies in hyponatremic animals have shown that the major osmolytes lost from the brain cells are the amino acids glutamine, glutamate, and taurine, and, to a lesser degree, the carbohydrate myoinositol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/4,15,16\">",
"     4,15,16",
"    </a>",
"    ]. A study using proton NMR spectroscopy found a slightly different pattern in humans with chronic hyponatremia; myoinositol and choline compounds were the primary organic solutes lost, with a smaller change occurring in glutamine and glutamate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/17\">",
"     17",
"    </a>",
"    ]. Myoinositol also appears to be the primary osmolyte taken up by the brain as part of the protective response in patients with hypernatremia. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Cerebral adaptation to hypernatremia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations of chronic hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cerebral adaptation permits patients with chronic hyponatremia to appear to be asymptomatic despite a serum sodium concentration below 120",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    When symptoms do occur in patients with serum sodium concentrations at this level, they are relatively nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/8,18,19\">",
"     8,18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Nausea",
"     </li>",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Gait disturbances",
"     </li>",
"     <li>",
"      Forgetfulness",
"     </li>",
"     <li>",
"      Confusion",
"     </li>",
"     <li>",
"      Lethargy",
"     </li>",
"     <li>",
"      Muscle cramps",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seizures and coma are uncommon and often reflect an acute exacerbation of the hyponatremia. Symptomatic chronic hyponatremia is rarely, if ever, associated with cerebral edema severe enough to cause herniation of the brain. In a series of 223 patients hospitalized for symptomatic chronic hyponatremia due to thiazide diuretics, there was a 1 percent incidence of seizures and no cases of herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=see_link\">",
"     \"Diuretic-induced hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The older literature includes reports of brain damage in outpatients with thiazide-induced hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/7\">",
"     7",
"    </a>",
"    ]. However, at the time of the study, the consequences of overly rapid correction were unknown. The reported patients were all treated with hypertonic saline, increasing the serum sodium concentration by more than 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 48 hours, a rate of correction that is associated with osmotic demyelination. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Osmotic demyelination'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Subtle manifestations in mild to moderate chronic hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate chronic hyponatremia often appear asymptomatic but may have subtle neurologic manifestations that can easily be missed. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SALT-1 and SALT-2 trials evaluated the efficacy of the oral vasopressin receptor antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"       tolvaptan",
"      </a>",
"      compared with placebo in patients with chronic hyponatremia; none of the patients had clinically apparent neurologic symptoms at baseline and almost all had a serum sodium concentration of 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or higher [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/20\">",
"       20",
"      </a>",
"      ]. Gradually raising the serum sodium with tolvaptan was associated with significant improvement on the Mental Component of the Medical Outcomes Study Short-Form General Health Survey at 30 days. This benefit was significant only in patients with a serum sodium concentration between 120 and 129",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      and was not seen with correction of mild hyponatremia (130 to 134",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      or in the placebo group. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A case control study found that elderly patients (mean age 72) with chronic mild to moderate hyponatremia (serum sodium concentration 120 to 130",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      mean 126",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      were more likely to have falls, which may have resulted from a higher rate of gait disturbance and attention deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/21\">",
"       21",
"      </a>",
"      ]. Serial studies in the same patients suggested improvement in symptoms when the serum sodium concentration was normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mild to moderate hyponatremia may contribute to fractures in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In addition to a higher risk of falls, patients with hyponatremia are more likely to have osteoporosis than patients without hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/23\">",
"     23",
"    </a>",
"    ]. The higher prevalence of osteoporosis may be due at least in part to loss of bone sodium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H27#H27\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Possible risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyponatremia, even if mild, is associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. This was best shown in a prospective cohort study of 98,311 patients hospitalized between 2000 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/24\">",
"     24",
"    </a>",
"    ]. Compared with normonatremic patients, hyponatremic patients (serum sodium 130 to 134",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 83 percent) had an increased risk of death during the initial hospitalization (adjusted odds ratio 1.47, 95% CI 1.3-1.6) and at one and five years (hazard ratios of 1.38 and 1.25, respectively). However, this study could not determine whether the hyponatremia was causally associated with mortality. Since most patients had only mild hyponatremia, it seems likely that hyponatremia was a marker for more severe underlying disease. Such a relationship has been clearly established in hyponatremic patients with heart failure or cirrhosis (",
"    <a class=\"graphic graphic_figure graphicRef55554 \" href=\"UTD.htm?29/6/29805\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link\">",
"     \"Hyponatremia in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Susceptibility of premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women and young children with acute postoperative hyponatremia may progress rapidly from minimal symptoms (headache and nausea) to respiratory arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/6,28\">",
"     6,28",
"    </a>",
"    ]. Cerebral edema and herniation have been found at autopsy, leading some authors to suggest a possible hormonally-mediated decrease in the degree of osmotic adaptation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/6,29\">",
"     6,29",
"    </a>",
"    ]. The observation that prepubertal boys and girls are at equal risk of symptomatic hyponatremia is compatible with the importance of sex hormones in conferring susceptibility to adult women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/30\">",
"     30",
"    </a>",
"    ]. Other factors may play a role, such as the size of the brain in relationship to the capacity of the cranial vault, and a more rapid onset of hyponatremia because of smaller body size with less muscle to &ldquo;buffer&rdquo; the excess water. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Osmotic demyelination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adaptation that returns the brain volume toward normal in chronic hyponatremia protects against the development of cerebral edema but also creates a potential problem when the serum sodium is therapeutically or spontaneously corrected. In this setting, an overly rapid increase in the serum sodium concentration can lead to an osmotic demyelination syndrome (also called central pontine myelinolysis, although demyelination is often more diffuse and does not necessarily involve the pons). These changes can lead to potentially severe neurologic symptoms that are usually delayed for two to six days after correction and may be irreversible. Thus, patients with symptomatic hyponatremia may initially demonstrate neurologic improvement with correction of the serum sodium but then show late deterioration. This complication of treatment may be reversed by relowering of the serum sodium (",
"    <a class=\"graphic graphic_figure graphicRef76131 \" href=\"UTD.htm?19/46/20206\">",
"     figure 3",
"    </a>",
"    ). These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H5#H5\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H12#H12\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Relowering the serum sodium to treat overly rapid correction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HYPERNATREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is basically a mirror image of hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/1,3,4,31\">",
"     1,3,4,31",
"    </a>",
"    ]. A rise in the serum sodium concentration and osmolality causes water movement out of the brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Manifestations of acute hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;With acute hypernatremia (eg, after the inadvertent infusion of hypertonic saline into a uterine vein during therapeutic abortion, or the ingestion of large amounts of salt) the rapid decrease in brain volume can cause rupture of the cerebral veins, leading to focal intracerebral and subarachnoid hemorrhages and possibly irreversible neurologic damage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/1,3,32\">",
"     1,3,32",
"    </a>",
"    ]. Acute hypernatremia can also result in demyelinating brain lesions similar to those associated with overly rapid correction of chronic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Osmotic demyelination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical manifestations of acute hypernatremia begin with lethargy, weakness, and irritability, and can progress to twitching, seizures, and coma. Severe symptoms usually require an acute elevation in the serum sodium concentration to above 158",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Values above 180",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    are associated with a high mortality rate, particularly in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cerebral adaptation to hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning on the first day, the initial reduction in brain volume is largely reversed due both to water movement from the cerebrospinal fluid into the brain (thereby increasing the interstitial volume) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/4,39\">",
"     4,39",
"    </a>",
"    ] and to the uptake of solutes by the cells (thereby pulling water into the cells and restoring the cell volume) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/4,40,41\">",
"     4,40,41",
"    </a>",
"    ]. The latter response involves an initial uptake of sodium and potassium salts, followed by the later accumulation of osmolytes, which in animals consists primarily of myoinositol, the amino acids glutamine, glutamate, and taurine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. Myoinositol and taurine are taken up from the extracellular fluid via an increase in the number of sodium-myoinositol and sodium-taurine cotransporters in the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]; the source of glutamine and glutamate (uptake from the extracellular fluid or production within the cells) is unknown. The net effect is that these osmolytes, which do not interfere with protein function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/17\">",
"     17",
"    </a>",
"    ], account for about 35 percent of the new cell solute [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report of an infant with an initial serum sodium concentration of 195",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    confirmed the general applicability of these observations to humans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/44\">",
"     44",
"    </a>",
"    ]. The patient was first studied using proton NMR spectroscopy on day four when the serum sodium concentration had fallen to 156",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    At this time, there was a 17",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    increase in brain osmolyte concentration, due primarily to the accumulation of myoinositol. The excess brain osmolyte concentration fell to 6",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    on day 7 and was normal by day 36.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H570048\">",
"    <span class=\"h2\">",
"     Manifestations of chronic hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in hyponatremia, the cerebral adaptation in hypernatremia has two important clinical consequences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic hypernatremia, which is defined as hypernatremia that has been present for more than a day, is much less likely to induce neurologic symptoms. Assessment of symptoms attributable to hypernatremia is often difficult because most affected adults have underlying neurologic disease. The latter is required to diminish the protective thirst mechanism that normally prevents the development of hypernatremia, even in patients with diabetes insipidus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"       \"Etiology and evaluation of hypernatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Correction of chronic hypernatremia must occur slowly to prevent rapid fluid movement into the brain and cerebral edema, changes that can lead to seizures and coma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/45\">",
"       45",
"      </a>",
"      ]. Although the brain cells can rapidly lose potassium and sodium in response to cell swelling, the loss of accumulated osmolytes and the water they obligate occurs more slowly [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/4,41\">",
"       4,41",
"      </a>",
"      ]. The loss of myoinositol, for example, requires both a reduction in the synthesis of new sodium-inositol cotransporters [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/42\">",
"       42",
"      </a>",
"      ] and the activation of a specific inositol efflux mechanism in the cell membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/46\">",
"       46",
"      </a>",
"      ]. The delayed clearance of osmolytes from the cell can predispose to cerebral edema if the serum sodium concentration is lowered too rapidly. As a result, the rate of correction in asymptomatic patients should be less than 10 to 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per day [",
"      <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hypernatremia\", section on 'Step two: choose a rate of correction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SENSING OF CHANGES IN PLASMA OSMOLALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the mechanisms of protective solute loss in hyponatremia and solute uptake in hypernatremia have been largely defined, the mechanisms by which the alterations in plasma osmolality are sensed by the cells (particularly brain cells) and then lead to the physiologically appropriate changes in solute content are not well understood. There is preliminary evidence that hyperosmolality, perhaps via stress on the cytoskeleton as the cell volume falls, activates a specific protein kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?22/58/23464/abstract/48\">",
"     48",
"    </a>",
"    ]. This kinase, via protein phosphorylation, may then lead to activation of transporters, such as the sodium-inositol cotransporter, that promote solute uptake into the cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=see_link\">",
"       \"Patient information: Hyponatremia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms associated with hyponatremia or hypernatremia are primarily neurologic and related to the severity and rapidity of the change in the serum sodium concentration. Such symptoms must be distinguished from those of concurrent volume depletion and possible underlying neurologic diseases that may predispose to the electrolyte abnormality. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <strong>",
"     Hyponatremia",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms directly attributable to hyponatremia reflect neurologic dysfunction induced by cerebral edema. Cerebral edema is due to a decrease in serum osmolality which causes water movement into cells.",
"     </li>",
"     <li>",
"      Clinical manifestations of acute hyponatremia reflect the severity of cerebral overhydration. Nausea and malaise are the earliest findings, and may be seen at a serum sodium concentration below 125 to 130",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Headache, lethargy, obtundation and eventually seizures, coma, and respiratory arrest may occur if the serum sodium concentration falls below 115 to 120",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Hyponatremic encephalopathy may be reversible or permanent. Premenopausal women appear to be at greater risk for severe hyponatremic symptoms and for residual neurologic injury. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations of acute hyponatremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Susceptibility of premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the cerebral adaptation, neurologic symptoms are much less severe with chronic hyponatremia. Patients with chronic hyponatremia may appear to be asymptomatic despite a serum sodium concentration that is persistently below 120",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Symptoms that do occur include fatigue, nausea, dizziness, gait disturbances, forgetfulness, confusion, lethargy, and muscle cramps. Seizures and coma are uncommon and often reflect an acute exacerbation of the hyponatremia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Osmolytes and cerebral adaptation to hyponatremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations of chronic hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic manifestations resulting from chronic hyponatremia, including gait disturbance and attention deficits, may result in increased falls among elderly patients. Even mild hyponatremia is associated with increased mortality, although the hyponatremia may just be a marker for more severe underlying disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Subtle manifestations in mild to moderate chronic hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An overly rapid increase in the serum sodium concentration can lead to osmotic demyelination syndrome (also called central pontine myelinolysis) resulting in severe and potentially irreversible neurologic symptoms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Osmotic demyelination'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link&amp;anchor=H5#H5\">",
"       \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Hypernatremia",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypernatremia causes water movement out of the brain resulting in a decrease in brain volume that, if acute, can cause focal intracerebral and subarachnoid hemorrhages, demyelinating brain lesions, and irreversible neurologic damage. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Manifestations of acute hypernatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypernatremic patients who become symptomatic present with lethargy, weakness and irritability, and may develop twitching, seizures, and coma. Severe symptoms usually require an acute elevation in the serum sodium concentration to above 158",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Values above 180",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      are associated with a high mortality rate, particularly in adults. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Manifestations of acute hypernatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the cerebral adaptation, chronic hypernatremia is less likely to induce neurologic symptoms. The correction of chronic hypernatremia must occur slowly to prevent rapid fluid movement into the brain and cerebral edema. The rate of correction in asymptomatic patients should not exceed 12",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per day, which represents an average of 0.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per hour. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cerebral adaptation to hypernatremia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hypernatremia\", section on 'Step two: choose a rate of correction'",
"      </a>",
"      .).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.716, 761.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/2\">",
"      Yeates KE, Singer M, Morton AR. Salt and water: a simple approach to hyponatremia. CMAJ 2004; 170:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/3\">",
"      McManus ML, Churchwell KB, Strange K. Regulation of cell volume in health and disease. N Engl J Med 1995; 333:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/4\">",
"      Strange K. Regulation of solute and water balance and cell volume in the central nervous system. J Am Soc Nephrol 1992; 3:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/5\">",
"      Manley GT, Fujimura M, Ma T, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000; 6:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/6\">",
"      Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 1992; 117:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/7\">",
"      Ashraf N, Locksley R, Arieff AI. Thiazide-induced hyponatremia associated with death or neurologic damage in outpatients. Am J Med 1981; 70:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/8\">",
"      Ellis SJ. Severe hyponatraemia: complications and treatment. QJM 1995; 88:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/9\">",
"      Moritz ML, Ayus JC. The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant 2003; 18:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/10\">",
"      Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med 2000; 132:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/11\">",
"      Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med 1997; 126:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/12\">",
"      Sterns RH, Thomas DJ, Herndon RM. Brain dehydration and neurologic deterioration after rapid correction of hyponatremia. Kidney Int 1989; 35:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/13\">",
"      Melton JE, Patlak CS, Pettigrew KD, Cserr HF. Volume regulatory loss of Na, Cl, and K from rat brain during acute hyponatremia. Am J Physiol 1987; 252:F661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/14\">",
"      Strange K, Jackson PS. Swelling-activated organic osmolyte efflux: a new role for anion channels. Kidney Int 1995; 48:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/15\">",
"      Lien YH, Shapiro JI, Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis. J Clin Invest 1991; 88:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/16\">",
"      Verbalis JG, Gullans SR. Hyponatremia causes large sustained reductions in brain content of multiple organic osmolytes in rats. Brain Res 1991; 567:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/17\">",
"      Videen JS, Michaelis T, Pinto P, Ross BD. Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study. J Clin Invest 1995; 95:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/18\">",
"      Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/19\">",
"      Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatremia. J Natl Med Assoc 2004; 96:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/20\">",
"      Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/21\">",
"      Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119:71.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/22\">",
"      Gankam Kengne F, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008; 101:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/23\">",
"      Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010; 25:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/24\">",
"      Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009; 122:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/25\">",
"      Wald R, Jaber BL, Price LL, et al. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010; 170:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/26\">",
"      Doshi SM, Shah P, Lei X, et al. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 2012; 59:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/27\">",
"      Leung AA, McAlister FA, Rogers SO Jr, et al. Preoperative hyponatremia and perioperative complications. Arch Intern Med 2012; 172:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/28\">",
"      Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986; 314:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/29\">",
"      Fraser CL, Kucharczyk J, Arieff AI, et al. Sex differences result in increased morbidity from hyponatremia in female rats. Am J Physiol 1989; 256:R880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/30\">",
"      Arieff AI, Ayus JC, Fraser CL. Hyponatraemia and death or permanent brain damage in healthy children. BMJ 1992; 304:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/31\">",
"      Adrogu&eacute; HJ, Madias NE. Hypernatremia. N Engl J Med 2000; 342:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/32\">",
"      Furukawa S, Takaya A, Nakagawa T, et al. Fatal hypernatremia due to drinking a large quantity of shoyu (Japanese soy sauce). J Forensic Leg Med 2011; 18:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/33\">",
"      Soupart A, Penninckx R, Namias B, et al. Brain myelinolysis following hypernatremia in rats. J Neuropathol Exp Neurol 1996; 55:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/34\">",
"      Brown WD, Caruso JM. Extrapontine myelinolysis with involvement of the hippocampus in three children with severe hypernatremia. J Child Neurol 1999; 14:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/35\">",
"      Chang L, Harrington DW, Milkotic A, et al. Unusual occurrence of extrapontine myelinolysis associated with acute severe hypernatraemia caused by central diabetes insipidus. Clin Endocrinol (Oxf) 2005; 63:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/36\">",
"      Odier C, Nguyen DK, Panisset M. Central pontine and extrapontine myelinolysis: from epileptic and other manifestations to cognitive prognosis. J Neurol 2010; 257:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/37\">",
"      van der Helm-van Mil AH, van Vugt JP, Lammers GJ, Harinck HI. Hypernatremia from a hunger strike as a cause of osmotic myelinolysis. Neurology 2005; 64:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/38\">",
"      Moder KG, Hurley DL. Fatal hypernatremia from exogenous salt intake: report of a case and review of the literature. Mayo Clin Proc 1990; 65:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/39\">",
"      Pullen RG, DePasquale M, Cserr HF. Bulk flow of cerebrospinal fluid into brain in response to acute hyperosmolality. Am J Physiol 1987; 253:F538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/40\">",
"      Heilig CW, Stromski ME, Blumenfeld JD, et al. Characterization of the major brain osmolytes that accumulate in salt-loaded rats. Am J Physiol 1989; 257:F1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/41\">",
"      Lien YH, Shapiro JI, Chan L. Effects of hypernatremia on organic brain osmoles. J Clin Invest 1990; 85:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/42\">",
"      Paredes A, McManus M, Kwon HM, Strange K. Osmoregulation of Na(+)-inositol cotransporter activity and mRNA levels in brain glial cells. Am J Physiol 1992; 263:C1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/43\">",
"      De Petris L, Luchetti A, Emma F. Cell volume regulation and transport mechanisms across the blood-brain barrier: implications for the management of hypernatraemic states. Eur J Pediatr 2001; 160:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/44\">",
"      Lee JH, Arcinue E, Ross BD. Brief report: organic osmolytes in the brain of an infant with hypernatremia. N Engl J Med 1994; 331:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/45\">",
"      Hogan GR, Dodge PR, Gill SR, et al. Pathogenesis of seizures occurring during restoration of plasma tonicity to normal in animals previously chronically hypernatremic. Pediatrics 1969; 43:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/46\">",
"      Strange K, Morrison R, Shrode L, Putnam R. Mechanism and regulation of swelling-activated inositol efflux in brain glial cells. Am J Physiol 1993; 265:C244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/47\">",
"      Fang C, Mao J, Dai Y, et al. Fluid management of hypernatraemic dehydration to prevent cerebral oedema: a retrospective case control study of 97 children in China. J Paediatr Child Health 2010; 46:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/58/23464/abstract/48\">",
"      Galcheva-Gargova Z, D&eacute;rijard B, Wu IH, Davis RJ. An osmosensing signal transduction pathway in mammalian cells. Science 1994; 265:806.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2287 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23464=[""].join("\n");
var outline_f22_58_23464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPONATREMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H238335439\">",
"      Importance of hypoosmolality in symptom development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations of acute hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Osmolytes and cerebral adaptation to hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations of chronic hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Subtle manifestations in mild to moderate chronic hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Susceptibility of premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Osmotic demyelination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HYPERNATREMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Manifestations of acute hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cerebral adaptation to hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H570048\">",
"      Manifestations of chronic hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SENSING OF CHANGES IN PLASMA OSMOLALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2287\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2287|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/22/26989\" title=\"figure 1\">",
"      Osmolytes and hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/6/29805\" title=\"figure 2\">",
"      Hyponatremia in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/46/20206\" title=\"figure 3\">",
"      Time course of ODS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=related_link\">",
"      Diuretic-induced hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1706?source=related_link\">",
"      Exercise-associated hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=related_link\">",
"      Patient information: Hyponatremia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_58_23465="Vancomycin: Pediatric drug information";
var content_f22_58_23465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vancomycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"    see \"Vancomycin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/34/17957?source=see_link\">",
"    see \"Vancomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vancocin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Vancomycin;",
"     </li>",
"     <li>",
"      Sterile Vancomycin Hydrochloride, USP;",
"     </li>",
"     <li>",
"      Val-Vancomycin;",
"     </li>",
"     <li>",
"      Vancocin&reg;;",
"     </li>",
"     <li>",
"      Vancomycin Hydrochloride for Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General dosing, susceptible infection: Note:",
"     </b>",
"     Consider single-dose administration with serum concentration monitoring rather than scheduled dosing in patients with urine output &lt;1 mL/kg/hour or if serum creatinine significantly increases from baseline (eg, doubles). Consider prolongation of dosing interval when coadministered with ibuprofen or indomethacin or in neonates with history of the following: Birth depression, birth hypoxia/asphyxia, or cyanotic congenital heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial dosage recommendation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Renal function-based dosing:  (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &le;28 weeks GA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.9 mg/dL: 15 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     0.9-1.1 mg/dL: 20 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     1.2-1.4 mg/dL: 15 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     1.5-1.8 mg/dL: 10 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.8 mg/dL: 15 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt; 28 weeks GA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.7 mg/dL: 15 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     0.7-0.9 mg/dL: 20 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     1-1.2 mg/dL: 15 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     1.3-1.6 mg/dL: 10 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;1.6 mg/dL: 15 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight-based dosing (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA &lt;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &lt;1200 g: 15 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     1200-2000 g: 10-15 mg/kg/dose every 12-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &gt;2000 g: 10-15 mg/kg/dose every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PNA &ge;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &lt;1200 g: 15 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     1200-2000 g: 10-15 mg/kg/dose every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &gt;2000 g: 10-15 mg/kg/dose every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ECMO, initial dosing in full-term neonates:",
"     </b>",
"     I.V.: 15-20 mg/kg/dose every 18-24 hours (Buck, 2003); closely monitor serum concentrations; more frequent dosing may be needed for some patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CNS Infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Meningitis (Tunkel, 2004):",
"     <b>",
"      Note:",
"     </b>",
"     Maintain trough serum concentrations of 15-20 mcg/mL; for neonates &lt; 2 kg, consider use of smaller doses and longer intervals. I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &le;7 days and &ge;2 kg: 20-30 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &gt;7days and &ge;2 kg: 30-45 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VP-shunt infection, ventriculitis: Limited data available: Intrathecal/intraventricular (",
"     <b>",
"      use a preservative-free preparation",
"     </b>",
"     ): 5-10 mg/day (Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Monitor vancomycin serum concentrations and adjust accordingly.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"      see \"Vancomycin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial dosage recommendation:",
"     <b>",
"      Note:",
"     </b>",
"     Doses require adjustment in renal impairment. Consider single-dose administration with serum concentration monitoring rather than scheduled dosing in patients with urine output &lt;1 mL/kg/hour, or serum creatinine &gt;1.3 mg/dL or if serum creatinine significantly increases from baseline (eg, doubles):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible infection",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"     <b>",
"      Note:",
"     </b>",
"     Every 6 hour dosing recommended as initial dosage regimen if targeting trough serum concentrations &gt;10 mcg/mL (Benner, 2009; Frymoyer, 2009) in patients with normal renal function. Close monitoring of serum concentrations and assurance of adequate hydration status is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild to moderate infection: I.V.: 40-45 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours; dose and frequency should be individualized based on serum concentrations; usual maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe infection: I.V.: 45-60 mg/kg/",
"     <b>",
"      da",
"     </b>",
"     y divided every 6-8 hours; dose and frequency should be individualized based on serum concentrations; usual maximum daily dose: 4000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bacteremia [",
"      <i>",
"       S. aureus",
"      </i>",
"      (methicillin-resistant)]:",
"     </b>",
"     I.V.: 15 mg/kg/dose every 6 hours for 2-6 weeks depending on severity (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bone and joint infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Osteomyelitis [",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant)]: I.V.: 15 mg/kg/dose every 6 hours for a minimum of 4-6 weeks (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Septic arthritis [",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant)]: I.V.: 15 mg/kg/dose every 6 hours for minimum of 3-4 weeks  (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: I.V.: 40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-12 hours for 4-6 weeks; dosage should be adjusted to target peak serum concentrations of 30-45 mcg/mL and trough serum concentrations of 10-15 mcg/mL; may combine with gentamicin for 2-6 weeks based on organism, resistance pattern and type of valve. (Baddour, 2005; Ferrieri, 2002).",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the AHA as an alternative agent in &beta;-lactam allergic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     AHA Guidelines: I.V.: 40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-12 hours for at least 6 weeks; dosage should be adjusted to target peak serum concentrations of 30-45 mcg/mL and trough serum concentrations of 10-15 mcg/mL;",
"     <b>",
"      Note:",
"     </b>",
"     For prosthetic valves, combination with rifampin for the entire duration of therapy and gentamicin for the first 2 weeks has been recommended (Baddour, 2005; Ferrieri, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     IDSA Guidelines: I.V.: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours for at least 6 weeks (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prophylaxis, GI or genitourinary procedures: I.V.: 20 mg/kg over 1 hour; complete infusion 30 minutes prior to the procedure (Wilson, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the AHA as an alternative agent in &beta;-lactam allergic patients. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Enterocolitis (",
"      <i>",
"       S. aureus",
"      </i>",
"      ):",
"     </b>",
"     Oral: 40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours for 7-10 days; maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Intra-abdominal infection, complicated (MRSA):",
"     </b>",
"     I.V.: 40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Peritonitis (CAPD)",
"     </b>",
"     (Warady, 2000): Intraperitoneal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermittent: 30 mg/kg/dose every 5-7 days;",
"     <b>",
"      Note:",
"     </b>",
"     Increased clearance may occur in patients with residual renal function; the second dose should be based on serum concentration obtained 3-5 days after the initial dose; redosing should occur when serum concentration &lt;12 mcg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous: Loading dose: 1000 mg per liter of dialysate; maintenance dose: 30 mg per liter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pneumonia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Community-acquired pneumonia (CAP): Infants &ge;3 months, Children, and Adolescents: I.V.: 40-60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     every 6-8 hours; dosing to achieve AUC/MIC &gt;400 has been recommended for treating moderate to severe MRSA infections (Bradley, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Alternate regimen:",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant): Infants, Children, and Adolescents: I.V.: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours for 7-21 days depending on severity (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Healthcare-associated pneumonia (HAP),",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant): I.V.: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours for 7-21 days depending on severity (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Septic thrombosis of cavernous or dural venous sinus [",
"      <i>",
"       S. aureus",
"      </i>",
"      (methicillin-resistant)]:",
"     </b>",
"     I.V.: 15 mg/kg/dose every 6 hours for 4-6 weeks (some experts combine with rifampin) (Lui, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin and skin structure infections, complicated: [MRSA or",
"      <i>",
"       S. aureus",
"      </i>",
"      (methicillin sensitive) in penicillin allergic patients]:",
"     </b>",
"     I.V.: 40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours (Stevens, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate regimen:",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant):  I.V.: 60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours for 7-14 days (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      CNS infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Brain abscess, subdural empyema, spinal epidural abscess [",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant)]:  I.V.: 15 mg/kg/dose every 6 hours for 4-6 weeks (some experts combine with rifampin) (Lui, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Meningitis: I.V.: 15 mg/kg/dose every 6 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Maintain trough serum concentrations of 15-20 mcg/mL (Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      S. aureus",
"     </i>",
"     (methicillin-resistant): 15 mg/kg/dose every 6 hours for 2 weeks (some experts combine with rifampin) (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     VP-shunt infection, ventriculitis: Limited data available: Intrathecal/intraventricular",
"     <b>",
"      (use a preservative-free preparation)",
"     </b>",
"     : 5-20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; usual dose: 10 or 20 mg/",
"     <b>",
"      day",
"     </b>",
"     (Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       C. difficile",
"      </i>",
"      -associated diarrhea (CDAD):",
"     </b>",
"     Oral: 40 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6-8 hours for 7-10 days; maximum daily dose: 2000 mg/",
"     <b>",
"      day",
"     </b>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     Metronidazole is initial drug of choice (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Initial intravenous dosing should be based on actual body weight; subsequent dosing adjusted based on serum trough vancomycin concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 2000-3000 mg/",
"     <b>",
"      day",
"     </b>",
"     (or 30-60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ) in divided doses every 8-12 hours (Rybak, 2009);",
"     <b>",
"      Note:",
"     </b>",
"     Dose requires adjustment in renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 500-2000 mg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Catheter-related infections:",
"     </b>",
"     Antibiotic lock technique (Mermel, 2009): 2 mg/mL &plusmn; 10 units heparin/mL",
"     <b>",
"      or",
"     </b>",
"     2.5 mg/mL &plusmn; 2500",
"     <b>",
"      or",
"     </b>",
"     5000 units heparin/mL",
"     <b>",
"      or",
"     </b>",
"     5 mg/mL &plusmn; 5000 units heparin/mL (preferred regimen); instill into catheter port with a volume sufficient to fill the catheter (2-5 mL).",
"     <b>",
"      Note:",
"     </b>",
"     May use SWI/NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W as diluents. Do not mix with any other solutions. Dwell times generally should not exceed 48 hours before renewal of lock solution. Remove lock solution prior to catheter use, then replace.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      <i>",
"       C. difficile",
"      </i>",
"      -associated diarrhea (CDAD):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Manufacturer recommendations: 125 mg 4 times daily  for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     IDSA guideline recommendations: Severe infection: 125 mg every 6 hours for 10-14 days; Severe, complicated infection: 500 mg every 6 hours with or without concurrent I.V. metronidazole. May consider vancomycin retention enema (in patients with complete ileus) (Cohen, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Complicated infections in seriously ill patients:",
"     </b>",
"     I.V.: Loading dose: 25-30 mg/kg (based on actual body weight) may be used to rapidly achieve target concentration; then 15-20 mg/kg/dose every 8-12 hours (Rybak, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treatment: I.V.: 1000 mg every 12 hours for 4-6 weeks; may combine with gentamicin for 2-6 weeks based on organism, resistance pattern and type of valve (Gould, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Prophylaxis (Wilson, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Dental, oral, or upper respiratory tract surgery: I.V.: 1000 mg 1 hour before surgery.",
"     <b>",
"      Note:",
"     </b>",
"     AHA guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     GI/GU procedure: I.V.: 1000 mg 1 hour prior to surgery; must be used in combination with gentamicin.",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, routine prophylaxis  for GI/GU procedures no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Enterocolitis (",
"      <i>",
"       S. aureus",
"      </i>",
"      ):",
"     </b>",
"     Oral: 500-2000 mg/",
"     <b>",
"      day",
"     </b>",
"     in 3-4 divided doses for 7-10 days (usual dose: 125-500 mg every 6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: 30-60 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses every 8-12 hours (Rybak, 2009)",
"     <b>",
"      or",
"     </b>",
"     500-750 mg every 6 hours (with third generation cephalosporin for PCN-resistant",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intrathecal, intraventricular: 5-20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      MRSA infections",
"     </b>",
"     (Liu, 2011): I.V.: 15-20 mg/kg/dose every 8-12 hours; duration of therapy dependent upon site of infection and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Susceptible (MIC &le;1 mcg/mL) gram-positive infections:",
"     </b>",
"     I.V.: 15-20 mg/kg/dose (usual: 750-1500 mg) every 8-12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     If MIC &ge;2 mcg/mL, alternative therapies are recommended (Rybak, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment: Vancomycin levels should be monitored in patients with any renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff, 2007):",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on doses of 10 mg/kg/dose every 6 hours or 15 mg/kg/dose every 8 hours:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR 30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 10 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 10 mg/kg/dose every 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 10 mg/kg/dose; redose based on serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermittent hemodialysis: 10 mg/kg/dose; redose based on serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis (PD):  10 mg/kg/dose; redose based on serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT): 10 mg/kg/dose every 12-24 hours; monitor serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Some experts suggest:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Start with 15-20 mg/kg/dose (usual: 750-1500 mg) every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-49 mL/minute: Start with 15-20 mg/kg/dose (usual: 750-1500 mg) every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Will need longer intervals; determine by serum concentration monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In the critically ill patient with renal insufficiency, the initial loading dose (25-30 mg/kg) should not be reduced; however, subsequent dosage adjustments should be made based on renal function and trough serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Poorly dialyzable by intermittent hemodialysis (0% to 5%); however, use of high-flux membranes and continuous renal replacement therapy (CRRT) increases vancomycin clearance and generally requires replacement dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Following loading dose of 15-25 mg/kg, give either 500-1000 mg or 5-10 mg/kg after each dialysis session. (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Redosing based on pre-HD serum concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &lt;10 mg/L: Administer 1000 mg after HD",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     10-25 mg/L: Administer 500-750 mg after HD",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     &gt;25 mg/L: Hold vancomycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Redosing based on post-HD serum concentrations: &lt;10-15 mg/L: Administer 500-1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis (PD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Administration via PD fluid: 15-30 mg/L (15-30 mcg/mL) of PD fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Systemic: Loading dose of 1000 mg, followed by 500-1000 mg every 48-72 hours with close monitoring of levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVH: Loading dose of 15-25 mg/kg, followed by either 1000 mg every 48 hours or 10-15 mg/kg every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVHD: Loading dose of 15-25 mg/kg, followed by either 1000 mg every 24 hours or 10-15 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CVVHDF: Loading dose of 15-25 mg/kg, followed by either 1000 mg every 24 hours or 7.5-10 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider redosing patients receiving CRRT for vancomycin serum concentrations &lt;10-15 mg/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Degrees of hepatic dysfunction do not affect the pharmacokinetics of vancomycin (Marti, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: No adjustment provided in the manufacturer&rsquo;s labeling",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 125 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vancocin&reg;: 125 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution: 500 mg (100 mL); 750 mg (150 mL); 1 g (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg, 750 mg, 1 g, 5 g, 10 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Vancomycin powder for injection may be reconstituted and used for oral administration (Cohen, 2010). Reconstituted powder for injection (not premixed solution) may be administered orally by diluting in 30 mL of water; common flavoring syrups may be added to improve taste. The unflavored, diluted solution may also be administered via nasogastric tube.  Also see Extemporaneously Prepared section.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Administer intermittent I.V. infusion over 60 minutes at a final concentration not to exceed 5 mg/mL; if a maculopapular rash appears on face, neck, trunk, and upper extremities, slow the infusion rate to administer dose over 90-120 minutes and increase the dilution volume; the reaction usually dissipates in 30-60 minutes; administration of antihistamines just before the infusion may also prevent or minimize this reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal/Intraventricular: Dilute in NS without preservatives to a final concentration between 2-5 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F233385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, allopurinol, alprostadil, amifostine, amiodarone, amsacrine, anidulafungin, atracurium, caspofungin, caffeine citrate, cisatracurium, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doripenem, doxapram, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, gallium nitrate, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, insulin (regular), labetalol, levofloxacin, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, meropenem, midazolam, milrinone, morphine, mycophenolate, nicardipine, ondansetron, oxytocin, paclitaxel, palonosetron, pancuronium, pemetrexed, remifentanil, sodium bicarbonate, tacrolimus, teniposide, theophylline, thiotepa, tigecycline, tolazoline, vecuronium, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Albumin, amphotericin B cholesteryl sulfate complex, bivalirudin, ciprofloxacin, drotrecogin alfa, idarubicin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin, ampicillin/sulbactam, aztreonam, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, foscarnet, heparin, methotrexate, nafcillin, pantoprazole, piperacillin, piperacillin/tazobactam, propofol, sargramostim, ticarcillin/clavulanate, TPN, warfarin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, pantoprazole.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone, dimenhydrinate, heparin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Powder for injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). After reconstitution, vials may be stored under refrigeration for 14 days.",
"     <b>",
"      Note:",
"     </b>",
"     Vials contain no bacteriostatic agent. Upon further dilution with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W, may refrigerate and use within 96 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premixed solution (manufacturer premixed): Store at -20&deg;C (-4&deg;F); once thawed, solutions are stable for 72 hours at room temperature or for 30 days refrigerated. Do not refreeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Capsules: Stored at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral:",
"     </b>",
"     Treatment of patients with the following infections or conditions: Infections due to documented or suspected methicillin-resistant",
"     <i>",
"      S. aureus",
"     </i>",
"     or beta-lactam resistant coagulase negative",
"     <i>",
"      Staphylococcus",
"     </i>",
"     ; serious or life-threatening infections (eg, endocarditis, meningitis, osteomyelitis) due to documented or suspected staphylococcal or streptococcal infections in patients who are allergic to penicillins and/or cephalosporins; empiric therapy of infections associated with central lines, VP shunts, hemodialysis shunts, vascular grafts, prosthetic heart valves (FDA approved in all ages)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"     Treatment of",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and enterocolitis caused by",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     (including methicillin-resistant strains) [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       I.V. vancomycin may be confused with INVanz&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Vancomycin may be confused with clindamycin, gentamicin, tobramycin, valACYclovir, vecuronium, Vibramycin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (intrathecal administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F233384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension accompanied by flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, drug fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythematous rash on face and upper body (red neck or red man syndrome)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, reversible neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Drug rash with eosinophilia and systemic symptoms (DRESS), ototoxicity (rare; use of other ototoxic agents may increase risk), renal failure (limited data suggesting direct relationship), Stevens-Johnson syndrome, thrombocytopenia, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, bad taste (with oral solution), diarrhea, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Creatinine increased, interstitial nephritis, ototoxicity, renal failure, renal impairment, thrombocytopenia, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vancomycin or any component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Premixed solutions: Hypersensitivity to corn or corn products",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment or those receiving other nephrotoxic or ototoxic drugs; dosage modification required in patients with impaired renal function. Chemical peritonitis syndrome has been reported with intraperitoneal administration.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause nephrotoxicity with intravenous therapy, although limited data suggest direct causal relationship; usual risk factors include pre-existing renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. Nephrotoxicity has also been reported following treatment with oral vancomycin (typically in patients &gt;65 years of age). If multiple sequential (&ge;2) serum creatinine concentrations demonstrate an increase of 0.5 mg/dL or &ge;50% increase from baseline (whichever is greater) in the absence of an alternative explanation, the patient should be identified as having vancomycin-induced nephrotoxicity (Rybak, 2009). Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible. Clinically significant serum concentrations have been reported in patients with inflammatory disorders of the intestinal mucosa who have taken oral vancomycin (multiple doses) for the treatment of",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea. Although use may be warranted, the risk for adverse reactions may be higher in this situation; consider monitoring serum trough concentrations, especially with renal insufficiency, severe colitis, concurrent rectal vancomycin administration, and/or concomitant I.V. aminoglycosides. The IDSA suggests that it is appropriate to obtain trough concentrations when a patient is receiving high doses (eg, &ge;2 g/day in adults) for prolonged courses  (Cohen, 2010). Accumulation may occur after multiple oral doses of vancomycin in patients with renal impairment; consider monitoring trough concentrations in this circumstance.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause neurotoxicity; usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications, advanced age, and dehydration. Ototoxicity, although rarely associated with monotherapy, is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Discontinue treatment if signs of ototoxicity occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Neutropenia has been reported; risk increased with prolonged therapy (&gt;1 week) or total doses exceeding 25 g in adults; prompt reversal of neutropenia is expected after discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral vancomycin is not effective for systemic infections; parenteral vancomycin is not effective for the treatment of colitis due to",
"     <i>",
"      C. difficile",
"     </i>",
"     and enterocolitis due to",
"     <i>",
"      S. aureus",
"     </i>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     In adults, the Infectious Disease Society of America (IDSA) recommends the use of oral metronidazole for initial treatment of mild to moderate",
"     <i>",
"      C. difficile",
"     </i>",
"     infection and the use of oral vancomycin for initial treatment of severe",
"     <i>",
"      C. difficile",
"     </i>",
"     infection (Cohen, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     IInfusion-related reaction may occur. Rapid infusion or doses &ge;15-20 mg/kg/hour associated with red neck or red man syndrome described as erythema multiforme-like reaction with intense pruritus, tachycardia, hypotension; rash involving face, neck, upper trunk, back, and upper arms; reaction usually dissipates in 30-60 minutes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Intravenous use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Vancomycin may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May diminish the therapeutic effect of Vancomycin. Management: Avoid concurrent administration of oral vancomycin and bile acid sequestrants when possible.  If use of both agents is necessary, consider separating doses by at least 2 hours to minimize the significance of the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Vancomycin may enhance the nephrotoxic effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Vancomycin may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Vancomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (oral); C (injection) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6833811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Vancomycin crosses the placenta and may result in therapeutic fetal concentrations. Adverse fetal effects, including hearing loss or nephrotoxicity, have not been reported following maternal use during pregnancy. A case report has been published of a vancomycin dose rapidly administered over ~3 minutes leading to maternal hypotension and fetal bradycardia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The pharmacokinetics of vancomycin may be altered during pregnancy and pregnant patients may need a higher dose of vancomycin. Maternal half-life is unchanged, but the volume of distribution and the total plasma clearance are increased. Individualization of therapy through serum concentration monitoring may be warranted. Vancomycin is recommended as an alternative agent to prevent the transmission of group B streptococcal (GBS) disease from mothers to newborns.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal function tests (especially when targeting higher serum concentrations), urinalysis, serum vancomycin concentrations, WBC; audiogram (in patients who concurrently receive ototoxic chemotherapy); fluid status",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1050539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Measure trough serum concentrations to assess efficacy. Peak concentrations may be helpful in the setting of atypical pharmacokinetic profile. Trough serum concentration typically obtained at steady state (ie, prior to the fourth dose). Target trough serum concentration may vary depending on organism, MIC, source of infection, and/or other patient factors (Rybak, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     15-20 mcg/mL: For organisms with an MIC = 1 mcg/mL or complicated infections (bacteremia, endocarditis, osteomyelitis, meningitis, and hospital-acquired pneumonia caused by",
"     <i>",
"      Staphylococcus",
"     </i>",
"     spp.) (Rybak, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     10-15 mcg/mL: Current recommendation for all other infections with an organism with an MIC &lt;1 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-10 mcg/mL: Traditional recommendation; may be adequate to treat some infections based on site and MIC; however, this range is not recommended in the adult guidelines for vancomycin use due to resistance development potential",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Although AUC/MIC is the preferred method to determine clinical effectiveness, trough serum concentrations may be used as a surrogate marker and is recommended as the most accurate and practical method of vancomycin monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis; alters bacterial-cell-membrane permeability; blocks glycopeptide polymerization of the phosphodisaccharide-pentapeptide complex in the second stage of cell wall synthesis by binding tightly to D-alanyl-D-alanine portion of cell wall precursor",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F9751005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Displays time-dependent antimicrobial killing; slowly bacteriocidal",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Poor; may be enhanced with bowel inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Erratic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intraperitoneal: Can result in 38% systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Wide and variable distribution in body tissues and fluids including pericardial, pleural, ascites, and synovial fluids; low concentration in CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonate, term: 0.57-0.69 L/kg (de Hoog, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates, receiving ECMO (mean age: ~39 weeks): Variable; 1.1 L/kg (range: 0.6-2.1 L/kg) (Amaker, 1996); others have reported lower values: 0.45 &plusmn; 0.18 L/kg (Buck, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients: Median: 0.57 L/kg (range: 0.26-1.05 L/kg) (Marsot, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult: 0.4-1 L/kg (Rybak, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relative diffusion from blood into CSF: Distribution improved with inflamed meninges and typically exceeds usual MICs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CSF concentrations: 0.2-17.3 mcg/mL (de Hoog, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CSF:blood level ratio: Normal meninges: Nil;  Inflamed meninges: 7.1% to 68% (de Hoog, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Uninflamed meninges: 0-4 mcg/mL; serum concentration dependent (Rybak, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Inflamed meninges: 6-11 mcg/mL; serum concentration dependent (Rybak, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CSF:blood level ratio: Normal meninges: Nil; Inflamed meninges: 20% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &lt;3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, biphasic: Prolonged significantly with reduced renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Newborns: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3 months to 4 years: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;3 years: 2.2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 5-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily via glomerular filtration; excreted as unchanged drug in the urine (80% to 90%); oral doses are excreted primarily in the feces; presence of malignancy in children is associated with an increase in vancomycin clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 0.63-1.5 mL/minute/kg; dependent on GA and/or PMA (de Hoog, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates, receiving ECMO: 0.78 mL/minute/kg (range: 0.49-1.07 mL/minute/kg) (Amaker, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients: Median: 1.1 mL/minute/kg (range: 0.33-1.87 mL/minute/kg) (Marsot, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.71-1.31 mL/minute/kg (de Hoog, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Poorly dialyzable by intermittent hemodialysis (0% to 5%); however, use of high-flux membranes and continuous renal replacement therapy (CRRT) increases vancomycin clearance, and generally requires replacement dosing",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/34/17957?source=see_link\">",
"      see \"Vancomycin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report pain at infusion site; dizziness, fullness, or ringing in ears with I.V. use",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F9751064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     \"Red man syndrome,\" characterized by skin rash and hypotension, is not an allergic reaction but rather is associated with too rapid infusion of the drug. To alleviate or prevent the reaction, infuse vancomycin at a rate of &ge;30 minutes for each 500 mg of drug being administered (eg, 1 g over &ge;60 minutes); 1.5 g over &ge;90 minutes.  When treating pathogens with a vancomycin MIC &ge;2 mcg/mL, alternative antibiotics should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F14320792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Using a vial of vancomycin powder for injection (reconstituted to 50 mg/mL), add the appropriate volume for the dose to 30 mL of water and administer orally or via NG tube. For oral administration, common flavoring syrups may be added to improve taste.",
"    </p>",
"    <div class=\"reference\">",
"     Vancomycin Hydrochloride for Injection, USP (prescribing information), Schaumburg, Il, APP Pharmaceuticals, LLC, 2011.",
"    </div>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A vancomycin 25 mg/mL solution in Ora-Sweet&reg; and water (1:1) may be prepared by reconstituting vancomycin for injection with sterile water, then dilute with a 1:1 mixture of Ora-Sweet&reg; and distilled water to a final concentration of 25 mg/mL; transfer to amber prescription bottle. Stable for 75 days refrigerated or for 26 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Ensom MH, Decarie D, and Lakhani A, &ldquo;Stability of Vancomycin 25 mg/mL in Ora-Sweet and Water in Unit-Dose Cups and Plastic Bottles at 4&deg;C and 25&deg;C,&rdquo;",
"     <i>",
"      Can J Hosp Pharm",
"     </i>",
"     , 2010, 63(5):366-72.",
"     <span class=\"pubmed-id\">",
"      22479004",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Amaker RD, DiPiro JT, and Bhatia J, \"Pharmacokinetics of Vancomycin in Critically Ill Infants Undergoing Extracorporeal Membrane Oxygenation,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1996, 40(5):1139-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/8723454/pubmed\" id=\"8723454\" target=\"_blank\">",
"        8723454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, \"Treatment of Bacterial Meningitis,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1988, 81(6):904-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/3368290/pubmed\" id=\"3368290\" target=\"_blank\">",
"        3368290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, \"Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, 154.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, \"Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):e394-434.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benner KW, Worthington MA, Kimberlin DW, et al, \"Correlation of Vancomycin Dosing to Serum Concentrations in Pediatric Patients: A Retrospective Database Review,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2009, 14:86-93.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, \"Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2003, 42(5):403-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/12739981/pubmed\" id=\"12739981\" target=\"_blank\">",
"        12739981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, \"Vancomycin Pharmacokinetics in Neonates Receiving Extracorporeal Membrane oxygenation,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1998, 18(5):1082-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/9758319/pubmed\" id=\"9758319\" target=\"_blank\">",
"        9758319",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang D, \"Influence of Malignancy on the Pharmacokinetics of Vancomycin in Infants and Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(8):667-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/ 8532423 /pubmed\" id=\" 8532423 \" target=\"_blank\">",
"        8532423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang D, Liem L, and Malogolowkin M, \"A Prospective Study of Vancomycin Pharmacokinetics and Dosage Requirements in Pediatric Cancer Patients,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1994, 13(11):969-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/7845750/pubmed\" id=\"7845750\" target=\"_blank\">",
"        7845750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen SH, Gerding DN, Johnson S, et al, \"Clinical Practice Guidelines for",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA),\"",
"      <i>",
"       Infect Control Hosp Epidemiol",
"      </i>",
"      , 2010, 31(5):431-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/20307191/pubmed\" id=\"20307191\" target=\"_blank\">",
"        20307191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Hoog M, Mouton JW, and van den Anker JN, \"Vancomycin: Pharmacokinetics and Administration Regimens in Neonates,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2004, 43(7):417-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/15139793/pubmed\" id=\"15139793\" target=\"_blank\">",
"        15139793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrieri P, Gewitz MH, Gerber MA, et al, \"Unique Features of Infective Endocarditis in Childhood,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(17):2115-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/11980694/pubmed\" id=\"11980694\" target=\"_blank\">",
"        11980694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frymoyer A, Hersh AL, Benet LZ, et al, \"Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections Is Inadequate,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(5):398-402.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/19295465/pubmed\" id=\"19295465\" target=\"_blank\">",
"        19295465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, \"Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, Koren G, Stevenson DK, et al, \"Vancomycin Pharmacokinetics in Very Low Birth Weight Neonates,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1989, 8(5):282-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/2657617/pubmed\" id=\"2657617\" target=\"_blank\">",
"        2657617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marsot A, Boulamery A, Bruguerolle B, et al, \"Vancomycin: A Review of Population Pharmacokinetic Analyses,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2012, 51(1):1-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/22149255/pubmed\" id=\"22149255\" target=\"_blank\">",
"        22149255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mart&iacute; R, Rosell M, Pou L, et al, \"Influence of Biochemical Parameters of Liver Function on Vancomycin pharmacokinetics,\"",
"      <i>",
"       Pharmacol Toxicol",
"      </i>",
"      , 1996, 79(2):55-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/8878246/pubmed\" id=\"8878246\" target=\"_blank\">",
"        8878246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matzke GR, Zhanel GG, and Guay DRP, \"Clinical Pharmacokinetics of Vancomycin,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1986, 11(4):257-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/3530582/pubmed\" id=\"3530582\" target=\"_blank\">",
"        3530582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mermel LA, Allon M, Bouza E, et al, \"Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(1):1-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/19489710/pubmed\" id=\"19489710\" target=\"_blank\">",
"        19489710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Antibacterial Drugs Dosage Tables,\" 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, 808-16.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodvold KA, Everett JA, Pryka RD, and Kraus DM, \"Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1997, 33(1):32-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/9250422/pubmed\" id=\"9250422\" target=\"_blank\">",
"        9250422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rybak MJ, Albrecht LM, Boike SC, et al, \"Nephrotoxicity of Vancomycin, Alone and With an Aminoglycoside,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1990, 25(4):679-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/2351627/pubmed\" id=\"2351627\" target=\"_blank\">",
"        2351627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rybak M, Lomaestro B, Rotschafer JC, et al, \"Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists,\"",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2009, 66(1):82-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/19106348/pubmed\" id=\"19106348\" target=\"_blank\">",
"        19106348",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, \"Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, Bisno AL, Chambers HF, et al, \"Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(10):1373-406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/16231249/pubmed\" id=\"16231249\" target=\"_blank\">",
"        16231249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41:1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, \"Practice Guidelines for the Management of Bacterial Meningitis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Schaefer F, Holloway M, et al, \"Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2000, 20(6):610-24.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, \"Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(15):1736-54. Available at file://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23465/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12874 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-124.240.187.80-1825C1B6E2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23465=[""].join("\n");
var outline_f22_58_23465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233330\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233331\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050536\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445215\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050528\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233306\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233291\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050541\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233385\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050531\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050540\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233387\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233384\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050544\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050527\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050526\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300205\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233300\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233302\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6833811\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050535\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050539\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050525\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9751005\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050543\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050533\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9751064\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14320792\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12874\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12874|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=related_link\">",
"      Vancomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/34/17957?source=related_link\">",
"      Vancomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_58_23466="Amiodarone: Drug information";
var content_f22_58_23466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amiodarone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27189?source=see_link\">",
"    see \"Amiodarone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"    see \"Amiodarone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cordarone&reg;;",
"     </li>",
"     <li>",
"      Nexterone&reg;;",
"     </li>",
"     <li>",
"      Pacerone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amiodarone Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Apo-Amiodarone&reg;;",
"     </li>",
"     <li>",
"      Ava-Amiodarone;",
"     </li>",
"     <li>",
"      Cordarone&reg;;",
"     </li>",
"     <li>",
"      Dom-Amiodarone;",
"     </li>",
"     <li>",
"      Mylan-Amiodarone;",
"     </li>",
"     <li>",
"      PHL-Amiodarone;",
"     </li>",
"     <li>",
"      PMS-Amiodarone;",
"     </li>",
"     <li>",
"      PRO-Amiodarone;",
"     </li>",
"     <li>",
"      ratio-Amiodarone;",
"     </li>",
"     <li>",
"      Riva-Amiodarone;",
"     </li>",
"     <li>",
"      Sandoz-Amiodarone;",
"     </li>",
"     <li>",
"      Teva-Amiodarone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Lower loading and maintenance doses are preferable in women and all patients with low body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation pharmacologic cardioversion (ACC/AHA/ESC Practice Guidelines) (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"     <i>",
"      Inpatient:",
"     </i>",
"     1.2-1.8 g/day in divided doses until 10 g total, then 200-400 mg/day maintenance.",
"     <i>",
"      Outpatient:",
"     </i>",
"     600-800 mg/day in divided doses until 10 g total, then 200-400 mg/day maintenance; although not supported by clinical evidence, a maintenance dose of 100 mg/day is commonly used especially for the elderly or patients with low body mass (Fuster, 2006; Zimetbaum, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Other regimens have been described and may be used clinically:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     400 mg 3 times/day for 5-7 days, then 400 mg/day for 1 month, then 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10 mg/kg/day for 14 days, followed by 300 mg/day for 4 weeks, followed by maintenance dosage of 200 mg/day (Roy, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 5-7 mg/kg over 30-60 minutes, then 1.2-1.8 g/day continuous infusion or in divided oral doses until 10 g total. Maintenance: See oral dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation prophylaxis following open heart surgery (unlabeled use): Note:",
"     </b>",
"     A variety of regimens have been used in clinical trials, including oral and intravenous regimens:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Starting in postop recovery, 400 mg twice daily for up to 7 days. Alternative regimen of amiodarone: 600 mg/day for 7 days prior to surgery, followed by 200 mg/day until hospital discharge, has also been shown to decrease the risk of postoperative atrial fibrillation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Starting at postop recovery, 1000 mg infused over 24 hours for 2 days has been shown to reduce the risk of postoperative atrial fibrillation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recurrent atrial fibrillation (unlabeled use):",
"     </b>",
"     No standard regimen defined; examples of regimens include: Oral: Initial: 10 mg/kg/day for 14 days; followed by 300 mg/day for 4 weeks, followed by maintenance dosage of 200 mg/day (Roy, 2000). Other regimens have been described and are used clinically (ie, 400 mg 3 times/day for 5-7 days, then 400 mg/day for 1 month, then 200 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ventricular arrhythmias:",
"     </b>",
"     Oral: 800-1600 mg/day in 1-2 doses for 1-3 weeks, then when adequate arrhythmia control is achieved, decrease to 600-800 mg/day in 1-2 doses for 1 month; maintenance: 400 mg/day; lower doses are recommended for supraventricular arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pulseless VT or VF (ACLS, 2010):",
"     </b>",
"     I.V. push, I.O.: Initial: 300 mg rapid bolus; if pulseless VT or VF continues after subsequent defibrillation attempt or recurs, administer supplemental dose of 150 mg.",
"     <b>",
"      Note:",
"     </b>",
"     In this setting, administering",
"     <b>",
"      undiluted",
"     </b>",
"     is preferred (Dager, 2006; Skrifvars, 2004).",
"     <i>",
"      The Handbook of Emergency Cardiovascular Care",
"     </i>",
"     (Hazinski, 2010) and the 2010 ACLS guidelines, do not make any specific recommendations regarding dilution of amiodarone in this setting. Experience limited with I.O. administration of amiodarone (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Upon return of spontaneous circulation,",
"     </i>",
"     follow  with an infusion of 1 mg/minute for 6 hours, then 0.5 mg/minute for 18 hours (mean daily doses &gt;2.1 g/day have been associated with hypotension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stable VT or SVT (unlabeled use):",
"     </b>",
"     First 24 hours: 1050 mg according to following regimen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Step 1: 150 mg (100 mL) over first 10 minutes (mix 3 mL in 100 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Step 2: 360 mg (200 mL) over next 6 hours (mix 18 mL in 500 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W): 1 mg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Step 3: 540 mg (300 mL) over next 18 hours: 0.5 mg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     After the first 24 hours: 0.5 mg/minute utilizing concentration of 1-6 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Breakthrough stable VT or SVT:",
"     </i>",
"     150 mg supplemental doses in 100 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS over 10 minutes (mean daily doses &gt;2.1 g/day have been associated with hypotension)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     I.V. to oral therapy conversion: Use the following as a guide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1-week I.V. infusion: 800-1600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1- to 3-week I.V. infusion: 600-800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;3-week I.V. infusion: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Conversion from I.V. to oral therapy has not been formally evaluated. Some experts recommend a 1-2 day overlap when converting from I.V. to oral therapy especially when treating ventricular arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Recommendations for conversion to intravenous amiodarone after oral administration:",
"     </b>",
"     During long-term amiodarone therapy (ie, &ge;4 months), the mean plasma-elimination half-life of the active metabolite of amiodarone is 61 days. Replacement therapy may not be necessary in such patients if oral therapy is discontinued for a period &lt;2 weeks, since any changes in serum amiodarone concentrations during this period may",
"     <b>",
"      not",
"     </b>",
"     be clinically significant.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F133657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"      see \"Amiodarone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arrhythmias (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Loading dose:",
"     </i>",
"     Oral: 10-20 mg/kg/day in 1-2 doses for 4-14 days or until adequate control of arrhythmia or prominent adverse effects occur; alternative loading dose in children &lt;1 year: 600-800 mg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 1-2 divided doses/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     Oral: Dose may be reduced to 5 mg/kg/day for several weeks (or 200-400 mg/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     /day given once daily); if no recurrence of arrhythmia, dose may be further reduced to 2.5 mg/kg/day; maintenance doses may be given 5-7 days/week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arrhythmias (unlabeled use, dosing based on limited data):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Loading dose:",
"     </i>",
"     I.V.: 5 mg/kg over 30 minutes; may repeat up to 3 times if no response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     I.V.: Continuous infusion: 10-20 mg/kg/day followed by conversion to oral therapy as appropriate.",
"     <b>",
"      Note:",
"     </b>",
"     Maximum recommended total daily dose in adolescents is 2.2 g.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. administration at low flow rates (potentially associated with use in pediatrics) may result in leaching of plasticizers (DEHP) from intravenous tubing. DEHP may adversely affect male reproductive tract development. Alternative means of dosing and administration (1 mg/kg aliquots) may need to be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pulseless VT or VF (PALS dosing):",
"     </b>",
"     I.V., I.O.: 5 mg/kg (maximum: 300 mg/dose) rapid bolus; repeat up to a maximum total dose of 15 mg/kg during acute treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Perfusing tachycardias (PALS dosing):",
"     </b>",
"     I.V., I.O.: Loading dose: 5 mg/kg (maximum: 300 mg/dose) over 20-60 minutes; may repeat up to maximum total dose of 15 mg/kg during acute treatment.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No specific guidelines available. Dose selection should be cautious, at low end of dosage range, and titration should be slower to evaluate response. Although not supported by clinical evidence, a maintenance dose of 100 mg/day is commonly used especially for the elderly or patients with low body mass (Fuster, 2006; Zimetbaum, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F133636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F133637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustment is probably necessary in substantial hepatic impairment. No specific guidelines available. If hepatic enzymes exceed 3 times normal or double in a patient with an elevated baseline, consider decreasing the dose or discontinuing amiodarone.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nexterone&reg;: 150 mg (100 mL); 360 mg (200 mL) [contains cyclodextrin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 50 mg/mL (3 mL, 9 mL, 18 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cordarone&reg;: 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacerone&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pacerone&reg;: 200 mg, 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cordarone&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152841.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152841.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Pacerone&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088668.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088668.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F133603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer consistently with regard to meals. Take in divided doses with meals if GI upset occurs or if taking large daily dose. If GI intolerance occurs with single-dose therapy, use twice daily dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: For infusions &gt;1 hour, use concentrations &le;2 mg/mL unless a central venous catheter is used; commercially-prepared premixed solutions in concentrations of 1.5 mg/mL and 1.8 mg/mL are available. Use only volumetric infusion pump; use of drop counting may lead to underdosage. Administer through an I.V. line located as centrally as possible. For continuous infusions, an in-line filter has been recommended during administration to reduce the incidence of phlebitis. During pulseless VT/VF, administering",
"     <b>",
"      undiluted",
"     </b>",
"     is preferred (Dager, 2006; Skrifvars, 2004).",
"     <i>",
"      The Handbook of Emergency Cardiovascular Care",
"     </i>",
"     (Hazinski, 2010) and the 2010 ACLS guidelines do not make any specific recommendations regarding dilution of amiodarone in this setting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adjust administration rate to urgency (give more slowly when perfusing arrhythmia present). Slow the infusion rate if hypotension or bradycardia develops. Infusions &gt;2 hours must be administered in a non-PVC container (eg, glass or polyolefin). PVC tubing is recommended for administration regardless of infusion duration.",
"     <b>",
"      Note:",
"     </b>",
"     I.V. administration at lower flow rates (potentially associated with use in pediatrics) and higher concentrations than recommended may result in leaching of plasticizers (DEHP) from intravenous tubing. DEHP may adversely affect male reproductive tract development. Alternative means of dosing and administration (1 mg/kg aliquots) may need to be considered.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     450 mg in 250 mL (concentration: 1.8 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1.8 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F133689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Variable stability (consult detailed reference):",
"     </b>",
"     D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Compatible:",
"     </b>",
"     Amikacin, amphotericin B, atracurium, atropine, calcium chloride, calcium gluconate, caspofungin, ciprofloxacin, clindamycin, dexmedetomidine, diltiazem, dobutamine, dopamine, doripenem, doxycycline, epinephrine, eptifibatide, erythromycin lactobionate, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, gentamicin, hetastarch in lactate electrolyte injection (Hextend&reg;), insulin (regular), isoproterenol, labetalol, lepirudin, lidocaine, lorazepam, methylprednisolone sodium succinate, metoprolol, metronidazole, midazolam, milrinone, morphine, nesiritide, nitroglycerin, norepinephrine, pancuronium, penicillin G potassium, phentolamine, phenylephrine, potassium chloride, procainamide, tirofiban, tobramycin, vancomycin, vasopressin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, ampicillin and sulbactam, argatroban, bivalirudin, ceftazidime, digoxin, drotrecogin alfa, heparin, imipenem and cilastatin, micafungin, pantoprazole, piperacillin, piperacillin and tazobactam, potassium phosphate, sodium bicarbonate, sodium phosphate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cefazolin, ceftriaxone, cefuroxime, furosemide, magnesium sulfate, nitroprusside.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Visually compatible (Chalmers, 2001):",
"     </b>",
"     Amphotericin B, atracurium, atropine, calcium chloride, calcium gluconate, ciprofloxacin, epinephrine, eptifibatide, famotidine, fentanyl citrate, fluconazole, furosemide (1 mg/mL), lepirudin, lorazepam, magnesium sulfate (20 mg/mL), methylprednisolone sodium succinate, milrinone, sodium nitroprusside, tirofiban, vasopressin, vecuronium.",
"     <b>",
"      Visually incompatible:",
"     </b>",
"     Ampicillin and sulbactam, ceftazidime, digoxin, furosemide (10 mg/mL), imipenem and cilastatin, magnesium sulfate (500 mg/mL), piperacillin, piperacillin and tazobactam, potassium phosphate, sodium phosphate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone, heparin, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of life-threatening recurrent ventricular fibrillation (VF) or hemodynamically-unstable ventricular tachycardia (VT) refractory to other antiarrhythmic agents or in patients intolerant of other agents used for these conditions",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F133678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atrial fibrillation (AF): Pharmacologic conversion of AF to and maintenance of normal sinus rhythm; treatment of AF in patients with heart failure [no accessory pathway] who require heart rate control (ACC/AHA/ESC Practice Guidelines) or in patients with hypertrophic cardiomyopathy (ACCF/AHA Practice Guidelines); prevention of postoperative AF associated with cardiothoracic surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paroxysmal supraventricular tachycardia (SVT) (not initial drug of choice)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ventricular tachyarrhythmias (ACLS/PALS guidelines): Cardiac arrest with persistent VT or VF if defibrillation, CPR, and vasopressor administration have failed; control of hemodynamically-stable monomorphic VT, polymorphic VT with a normal baseline QT interval, or wide-complex tachycardia of uncertain origin; control of rapid ventricular rate due to accessory pathway conduction in pre-excited atrial arrhythmias (ACLS guidelines) or stable narrow-complex tachycardia (ACLS guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adjunct to ICD therapy to suppress symptomatic ventricular tachyarrhythmias in otherwise optimally-treated patients with heart failure (ACC/AHA/ESC Practice Guidelines)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F133691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Amiodarone may be confused with aMILoride, inamrinone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cordarone&reg; may be confused with Cardura&reg;, Cordran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a recent meta-analysis, adult patients taking lower doses of amiodarone (152-330 mg daily for at least 12 months) were more likely to develop thyroid, neurologic, skin, ocular, and bradycardic abnormalities than those taking placebo (Vorperian, 1997). Pulmonary toxicity was similar in both the low-dose amiodarone group and in the placebo group, but there was a trend towards increased toxicity in the amiodarone group. Gastrointestinal and hepatic events were seen to a similar extent in both the low-dose amiodarone group and placebo group. As the frequency of adverse events varies considerably across studies as a function of route and dose, a consolidation of adverse event rates is provided by Goldschlager, 2000.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypotension (I.V. 16%, refractory in rare cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system (3% to 40%):  Abnormal gait/ataxia, dizziness, fatigue, headache, malaise, impaired memory, involuntary movement, insomnia, poor coordination, peripheral neuropathy, sleep disturbances, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Photosensitivity (10% to 75%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; Metabolic: Hypothyroidism (1% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, anorexia, and constipation (10% to 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST or ALT level &gt;2x normal (15% to 50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Corneal microdeposits (&gt;90%; causes visual disturbance in &lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: CHF (3%), bradycardia (3% to 5%), AV block (5%), conduction abnormalities, SA node dysfunction (1% to 3%), cardiac arrhythmia, flushing, edema. Additional effects associated with I.V. administration include asystole, atrial fibrillation, cardiac arrest, electromechanical dissociation, pulseless electrical activity (PEA), ventricular tachycardia, and cardiogenic shock.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Slate blue skin discoloration (&lt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperthyroidism (3% to 10%; more common in iodine-deficient regions of the world), libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abnormal salivation, abnormal taste (oral), diarrhea, nausea (I.V.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Coagulation abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatitis and cirrhosis (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis (I.V., with concentrations &gt;3 mg/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual disturbances (2% to 9%), halo vision (&lt;5% occurring especially at night), optic neuritis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary toxicity has been estimated to occur at a frequency between 2% and 7% of patients (some reports indicate a frequency as high as 17%). Toxicity may present as hypersensitivity pneumonitis; pulmonary fibrosis (cough, fever, malaise); pulmonary inflammation; interstitial pneumonitis; or alveolar pneumonitis. ARDS has been reported in up to 2% of patients receiving amiodarone, and postoperatively in patients receiving oral amiodarone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Abnormal smell (oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute intracranial hypertension (I.V.), acute renal failure, acute respiratory distress syndrome, agranulocytosis, alopecia, anaphylactic shock, angioedema, aplastic anemia,  bone marrow granuloma, bronchiolitis obliterans organizing pneumonia (BOOP), bronchospasm, cholestatic hepatitis, confusion, delirium, demyelinating polyneuropathy, disorientation, drug rash with eosinophilia and systemic symptoms (DRESS),  dyspnea, encephalopathy, eczema, eosinophilic pneumonia, epididymitis (noninfectious), erectile dysfunction, erythema multiforme, exfoliative dermatitis, fever, granuloma, hallucination, hemolytic anemia, hemoptysis, hyperglycemia, hypertriglyceridemia, hypotension (oral), hypoxia, impotence, injection site reactions, leukocytoclastic vasculitis, muscle weakness, myopathy, neutropenia, optic neuropathy, pancreatitis, pancytopenia, parkinsonian symptoms, photophobia, pleural effusion, pleuritis, proarrhythmia, pruritus, pseudotumor cerebri, pulmonary alveolar hemorrhage, pulmonary edema, pulmonary infiltrates, pulmonary mass, QT interval increased, rash, renal impairment, renal insufficiency, respiratory failure, rhabdomyolysis, SIADH, sinus arrest, skin cancer, spontaneous ecchymosis, Stevens-Johnson syndrome, thrombocytopenia, thyroid nodules, thyroid cancer, thyrotoxicosis, torsade de pointes (rare), toxic epidermal necrolysis, urticaria, vasculitis, ventricular fibrillation, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amiodarone, iodine, or any component of the formulation; severe sinus-node dysfunction; second- and third-degree heart block (except in patients with a functioning artificial pacemaker); bradycardia causing syncope (except in patients with a functioning artificial pacemaker); cardiogenic shock",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia/hypotension: May cause hypotension and bradycardia (infusion-rate related). Hypotension with rapid administration has been attributed to the emulsifier polysorbate 80. Commercially-prepared premixed solutions do not contain polysorbate 80 and may have a lower incidence of hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Liver toxicity is common, but usually mild with evidence of increased liver enzymes; severe liver toxicity can occur and has been fatal in a few cases.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optic neuritis/neuropathy: May cause optic neuropathy and/or optic neuritis, usually resulting in visual impairment. Corneal microdeposits occur in a majority of patients, and may cause visual disturbances in some patients (blurred vision, halos); these are not generally considered a reason to discontinue treatment. Corneal refractive laser surgery is generally contraindicated in amiodarone users (from manufacturers of surgical devices).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Avoid excessive exposure to sunlight; may cause photosensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects:",
"     <b>",
"      [U.S. Boxed Warning]: Amiodarone can exacerbate arrhythmias, by making them more difficult to tolerate or reverse;",
"     </b>",
"     other types of arrhythmias have occurred, including significant heart block, sinus bradycardia new ventricular fibrillation, incessant ventricular tachycardia, increased resistance to cardioversion, and polymorphic ventricular tachycardia associated with QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (torsade de pointes [TdP]). Risk may be increased with concomitant use of other antiarrhythmic agents or drugs that prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval. Proarrhythmic effects may be prolonged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Lung damage (abnormal diffusion capacity) may occur without symptoms;",
"     </b>",
"     monitor for pulmonary toxicity (eg, chronic interstitial pneumonitis, organizing pneumonia, acute respiratory distress syndrome, solitary pulmonary mass). Educate patients about monitoring for symptoms (eg, nonproductive cough, dyspnea, pleuritic pain, hemoptysis, wheezing, weight loss, fever, malaise). Evaluate new respiratory symptoms; pre-existing pulmonary disease does not increase risk of developing pulmonary toxicity, but if pulmonary toxicity develops then the prognosis is worse. Use of lower doses may be associated with a decreased incidence, but pulmonary toxicity has been reported in patients treated with low doses. The lowest effective dose should be used as appropriate for the acuity/severity of the arrhythmia being treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Appropriate use:",
"     <b>",
"      [U.S. Boxed Warnings]: Only indicated for patients with life-threatening arrhythmias because of risk of toxicity. Alternative therapies should be tried first before using amiodarone. Patients should be hospitalized when amiodarone is initiated.",
"     </b>",
"     Currently, the 2005 ACLS guidelines recommend I.V. amiodarone as the preferred antiarrhythmic for the treatment of pulseless VT/VF. In patients with non-life-threatening arrhythmias (eg, atrial fibrillation), amiodarone should be used only if the use of other antiarrhythmics has proven ineffective or are contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac devices (eg, implanted defibrillators, pacemakers): Chronic administration of antiarrhythmic drugs may affect defibrillation or pacing thresholds. Assess when initiating amiodarone and during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use very cautiously and with close monitoring in patients with thyroid disease; may cause hyper- or hypothyroidism. Hyperthyroidism may result in thyrotoxicosis and may aggravate or cause breakthrough arrhythmias. If any new signs of arrhythmia appear, hyperthyroidism should be considered. Thyroid function should be monitored prior to treatment and periodically thereafter, particularly in the elderly and in patients with underlying thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs metabolized by CYP enzymes: Amiodarone is a potent inhibitor of CYP enzymes and transport proteins (including p-glycoprotein), which may lead to increased serum concentrations/toxicity of a number of medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Particular caution must be used when a drug with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging potential relies on metabolism via enzymes amiodarone inhibits, since the effect of elevated concentrations may be additive with the effect of amiodarone. Carefully assess risk:benefit of coadministration of other drugs which may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Warfarin: Use caution when initiating amiodarone in patients on warfarin. Cases of increased INR with or without bleeding have occurred in patients treated with warfarin; monitor INR closely after initiating amiodarone in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use is associated with thyroid disease, pulmonary abnormalities, and QT-interval prolongation. In the treatment of atrial fibrillation, avoid antiarrhythmics as first-line treatment. In older adults, data suggests rate control may provide more benefits than risks compared to rhythm control for most patients (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Caution in surgical patients; may enhance hemodynamic effect of anesthetics; associated with increased risk of adult respiratory distress syndrome (ARDS) postoperatively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Vials for injection contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates. Commercially-prepared premixed solutions do not contain benzyl alcohol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Commercially-prepared premixed infusion: Contains the excipient cyclodextrin (sulfobutyl ether beta-cyclodextrin), which may accumulate in patients with renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CAST trial: In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, nonlife-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide. An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Use of amiodarone post-MI was not associated with an increase in mortality in two post-MI trials. Antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Patients may still be at risk for amiodarone&ndash;related drug interactions after the drug has been discontinued. The  pharmacokinetics are complex (due to prolonged duration of action and half-life) and difficult to predict.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F133676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (major), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (moderate), CYP2B6 (weak), CYP2C9 (moderate), CYP2D6 (moderate), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Alfa: Amiodarone may diminish the therapeutic effect of Agalsidase Alfa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Beta: Amiodarone may diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class Ia): Amiodarone may enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia).  Management: Risk of QTc prolongation and Torsades de Pointes may be increased; consider alternative therapy when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azithromycin (Systemic): May enhance the QTc-prolonging effect of Amiodarone. Management: The concomitant use of amiodarone, which has a high risk for QTc prolongation, with azithromycin, which may also prolong the QT interval, should be avoided.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Amiodarone may enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the bioavailability of Amiodarone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Amiodarone may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Amiodarone. Management: Consider alternatives to cimetidine. If this combination cannot be avoided, monitor for increased amiodarone concentrations/effects with cimetidine initiation/dose increase or decreased concentrations/effects with cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Amiodarone may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Amiodarone may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Amiodarone may increase the serum concentration of Dabigatran Etexilate.  Management: Canadian (but not U.S.) dabigatran prescribing information recommends limiting dabigatran dose for VTE prevention following hip/knee replacement to 150 mg/day.  No dose adjustment is recommended for dabigatran in atrial fibrillation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Amiodarone may increase the serum concentration of Flecainide.  Management: Decrease flecainide dose by 50% in the presence of amiodarone.  Monitor for adverse effects of flecainide and consider monitoring for elevated serum concentrations during concomitant therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Amiodarone may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease serum concentrations of the active metabolite(s) of Amiodarone. Grapefruit Juice may increase the serum concentration of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Amiodarone may decrease the metabolism of HMG-CoA Reductase Inhibitors.  Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Pravastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Amiodarone may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loratadine: Amiodarone may increase the serum concentration of Loratadine.  Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Amiodarone may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the absorption of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amiodarone may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Amiodarone may enhance the adverse/toxic effect of Propafenone. Specifically, the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Amiodarone may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May enhance the adverse/toxic effect of Amiodarone. Telaprevir may increase the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Amiodarone may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F133624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Increases the rate and extent of absorption of amiodarone. Grapefruit juice increases bioavailability of oral amiodarone by 50% and decreases the conversion of amiodarone to N-DEA (active metabolite); altered effects are possible. Management: Take consistenly with regard to meals; grapefruit juice should be avoided during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease amiodarone levels or enhance photosensitization. Ephedra may worsen arrythmia. Management: Avoid St John's wort, ephedra and dong quai.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm when administered to a pregnant woman, leading to congenital goiter and hypo- or hyperthyroidism.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F133611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothyroidism may occur in nursing infants. Both amiodarone and its active metabolite are excreted in human milk. Breast-feeding may lead to significant infant exposure and potential toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F133612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take consistently with regard to meals. Amiodarone is a potential source of large amounts of inorganic iodine; ~3 mg of inorganic iodine per 100 mg of amiodarone is released into the systemic circulation. Recommended daily allowance for iodine in adults is 150 mcg.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Grapefruit juice is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F133609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Amiodarone HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/3 mL (3 mL): $2.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     450 mg/9 mL (9 mL): $5.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     900 mg/18 mL (18 mL): $17.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nexterone Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/100 mL (100 mL): $39.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg/200 mL (200 mL): $52.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amiodarone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $198.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $158.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cordarone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $295.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pacerone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $222.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (90): $290.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $199.49",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F133595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate (ECG) and rhythm throughout therapy; assess patient for signs of  lethargy, edema of the hands or feet, weight loss, and pulmonary toxicity (baseline pulmonary function tests and chest X-ray; continue monitoring chest X-ray annually during therapy); liver function tests (semiannually); monitor serum electrolytes, especially potassium and magnesium. Assess thyroid function tests before initiation of treatment and then periodically thereafter (some experts suggest every 3-6 months). If signs or symptoms of thyroid disease or arrhythmia breakthrough/exacerbation occur then immediate re-evaluation is necessary. Amiodarone partially inhibits the peripheral conversion of thyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ) to triiodothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     ); serum T",
"     <sub>",
"      4",
"     </sub>",
"     and reverse triiodothyronine (rT",
"     <sub>",
"      3",
"     </sub>",
"     ) concentrations may be increased and serum T",
"     <sub>",
"      3",
"     </sub>",
"     may be decreased; most patients remain clinically euthyroid, however, clinical hypothyroidism or hyperthyroidism may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Perform regular ophthalmic exams.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients with implantable cardiac devices: Monitor pacing or defibrillation thresholds with initiation of amiodarone and during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F133599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 0.5-2.5 mg/L (SI: 1-4 micromole/L) (parent); desethyl metabolite is active and is present in equal concentration to parent drug",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldarin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Aldarone (TH);",
"     </li>",
"     <li>",
"      Amio (PH);",
"     </li>",
"     <li>",
"      Amiocar (AR);",
"     </li>",
"     <li>",
"      Amiodacore (IL);",
"     </li>",
"     <li>",
"      Amiodarex (DE);",
"     </li>",
"     <li>",
"      Amiodarona (CN);",
"     </li>",
"     <li>",
"      Amiohexal (DE);",
"     </li>",
"     <li>",
"      Amiorit (CO);",
"     </li>",
"     <li>",
"      Ancaron (JP);",
"     </li>",
"     <li>",
"      Angiodarona (BR);",
"     </li>",
"     <li>",
"      Angoron (GR);",
"     </li>",
"     <li>",
"      Anoion (PH);",
"     </li>",
"     <li>",
"      Aratac (AU, NZ, SG, TH, TW);",
"     </li>",
"     <li>",
"      Atlansil (AR, BR, CN, EC, PE, UY);",
"     </li>",
"     <li>",
"      Azoran (ID);",
"     </li>",
"     <li>",
"      Braxan (MX);",
"     </li>",
"     <li>",
"      Cardilor (MY, TH);",
"     </li>",
"     <li>",
"      Cardinorm (AU);",
"     </li>",
"     <li>",
"      Cardiorona (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Coedarone (MX);",
"     </li>",
"     <li>",
"      Corbionax (FR);",
"     </li>",
"     <li>",
"      Cordarex (DE);",
"     </li>",
"     <li>",
"      Cordarone (AE, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CO, CR, CY, CZ, DO, EC, EE, EG, ET, FI, FR, GH, GM, GN, GT, GY, HK, HN, ID, IQ, IR, IT, JM, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Cordarone X (AU, GB, IE, IN, NZ, ZA);",
"     </li>",
"     <li>",
"      Coronovo (AR);",
"     </li>",
"     <li>",
"      Daronal (CO);",
"     </li>",
"     <li>",
"      Diarona (UY);",
"     </li>",
"     <li>",
"      Escodaron (CH);",
"     </li>",
"     <li>",
"      Eurythmic (IN);",
"     </li>",
"     <li>",
"      Forken (MX);",
"     </li>",
"     <li>",
"      Hexarone (ZA);",
"     </li>",
"     <li>",
"      Kendaron (ID);",
"     </li>",
"     <li>",
"      Keritmon (MX);",
"     </li>",
"     <li>",
"      Myodial (PH);",
"     </li>",
"     <li>",
"      Procor (IL);",
"     </li>",
"     <li>",
"      Rithmik (AU);",
"     </li>",
"     <li>",
"      Rythma (PH);",
"     </li>",
"     <li>",
"      Sedacoron (AT, HK, TW);",
"     </li>",
"     <li>",
"      Tachydaron (DE);",
"     </li>",
"     <li>",
"      Tiaryt (ID);",
"     </li>",
"     <li>",
"      Trangorex (ES, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F133584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class III antiarrhythmic agent which inhibits adrenergic stimulation (alpha- and beta-blocking properties), affects sodium, potassium, and calcium channels, prolongs the action potential and refractory period in myocardial tissue; decreases AV conduction and sinus node function",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow and variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 2 days to 3 weeks; I.V.: May be more rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 1 week to 5 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration after discontinuing therapy: 7-50 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Mean onset of effect and duration after discontinuation may be shorter in children than adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 66 L/kg (range: 18-148 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C8 and 3A4 to active N-desethylamiodarone metabolite; possible enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 35% to 65%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 40-55 days (range: 26-107 days); shorter in children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Comparison of Antiarrhythmic-Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Near-Fatal Ventricular Arrhythmias. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(22):1576-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/9411221/pubmed\" id=\"9411221\" target=\"_blank\">",
"        9411221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bink-Boelkens MT, &ldquo;Pharmacologic Management of Arrhythmias,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2000, 21(6):508-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/11050274/pubmed\" id=\"11050274\" target=\"_blank\">",
"        11050274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(15):1871-909.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/14557344/pubmed\" id=\"14557344\" target=\"_blank\">",
"        14557344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boutitie F, Boissel JP, Connolly SJ, et al, &ldquo;Amiodarone Interaction With Beta-Blockers: Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Databases. The EMIAT and CAMIAT Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(17):2268-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/10226092/pubmed\" id=\"10226092\" target=\"_blank\">",
"        10226092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cairns JA, Connolly SJ, Roberts G, et al, &ldquo;Randomised Trial of Outcome After Myocardial Infarction in Patients With Frequent or Repetitive Ventricular Premature Depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1997, 349(9053):675-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/9078198/pubmed\" id=\"9078198\" target=\"_blank\">",
"        9078198",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chalmers JR, Bobek MB, and Militello MA, &ldquo;Visual Compatibility of Amiodarone Hydrochloride Injection With Various Intravenous Drugs,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2001, 58(6):504-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/11286148/pubmed\" id=\"11286148\" target=\"_blank\">",
"        11286148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coumel P and Fidelle J, &ldquo;Amiodarone in the Treatment of Cardiac Arrhythmias in Children: One Hundred Thirty-Five Cases,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1980, 100(6 Pt 2):1063-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/7446409/pubmed\" id=\"7446409\" target=\"_blank\">",
"        7446409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dager WE, Sanoski CA, Wiggins BS, et al, &ldquo;Pharmacotherapy Considerations in Advanced Cardiac Life Support,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(12):1703-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/17125434/pubmed\" id=\"17125434\" target=\"_blank\">",
"        17125434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daoud EG, Strickberger SA, Man KC, et al, &ldquo;Preoperative Amiodarone as Prophylaxis Against Atrial Fibrillation After Heart Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(25):1785-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/9400034/pubmed\" id=\"9400034\" target=\"_blank\">",
"        9400034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deedwania PC, Singh BN, Ellenbogen K, et al, &ldquo;Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation: Observations From the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(23):2574-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/9843465/pubmed\" id=\"9843465\" target=\"_blank\">",
"        9843465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dorian P, Cass D, Schwartz B, et al, &ldquo;Amiodarone as Compared With Lidocaine for Shock-Resistant Ventricular Fibrillation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(12):884-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/11907287/pubmed\" id=\"11907287\" target=\"_blank\">",
"        11907287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doval HC, Nul DR, Grancelli HO, et al, &ldquo;Randomised Trial of Low-Dose Amiodarone in Severe Congestive Heart Failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 344(8921):493-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/7914611/pubmed\" id=\"7914611\" target=\"_blank\">",
"        7914611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Prophylactic Amiodarone on Mortality After Acute Myocardial Infarction and in Congestive Heart Failure: Meta-analysis of Individual Data From 6500 Patients in Randomised Trials: Amiodarone Trials Meta-analysis Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1997, 350(9089):1417-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/9371164/pubmed\" id=\"9371164\" target=\"_blank\">",
"        9371164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Etheridge SP, Craig JE, and Compton SJ, &ldquo;Amiodarone Is Safe and Highly Effective Therapy for Supraventricular Tachycardia in Infants,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2001, 141(1):105-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/11136494/pubmed\" id=\"11136494\" target=\"_blank\">",
"        11136494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Figa FH, Gow RM, Hamilton RM, et al, &ldquo;Clinical Efficacy and Safety of Intravenous Amiodarone in Infants and Children,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1994, 74(6):573-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/8074040/pubmed\" id=\"8074040\" target=\"_blank\">",
"        8074040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garson A Jr, Gillette PC, McVey P, et al, &ldquo;Amiodarone Treatment of Critical Arrhythmias in Children and Young Adults,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1984, 4(4):749-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/6384328/pubmed\" id=\"6384328\" target=\"_blank\">",
"        6384328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldschlager N, Epstein AE, Naccarelli G, et al, &ldquo;Practical Guidelines for Clinicians Who Treat Patients With Amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(12):1741-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/10871966/pubmed\" id=\"10871966\" target=\"_blank\">",
"        10871966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guarnieri T, Nolan S, Gottlieb SO, et al, &ldquo;Intravenous Amiodarone for the Prevention of Atrial Fibrillation After Open Heart Surgery: The Amiodarone Reduction in Coronary Heart (ARCH) Trial,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 34(2):343-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/10440143/pubmed\" id=\"10440143\" target=\"_blank\">",
"        10440143",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hazinski MF, Samson R, and Schexnayder S,",
"      <i>",
"       2010 Handbook of Emergency Cardiovascular Care for Healthcare Providers",
"      </i>",
"      , South Deerfield, MA: American Heart Association; 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Julian DG, Camm AJ, Frangin G, et al, &ldquo;Randomised Trial of Effect of Amiodarone on Mortality in Patients With Left-Ventricular Dysfunction After Recent Myocardial Infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1997, 349(9053):667-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/9078197/pubmed\" id=\"9078197\" target=\"_blank\">",
"        9078197",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kennedy RL, Griffiths H, Gray TA, et al, &ldquo;Amiodarone and the Thyroid,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1989, 35(9):1882-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/2673586/pubmed\" id=\"2673586\" target=\"_blank\">",
"        2673586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kowey PR, Levine JH, Herre JM, et al, &ldquo;Randomized, Double-Blind Comparison of Intravenous Amiodarone and Bretylium in the Treatment of Patients With Recurrent, Hemodynamically Destabilizing Ventricular Tachycardia or Fibrillation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1995, 92(11):3255-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/7586312/pubmed\" id=\"7586312\" target=\"_blank\">",
"        7586312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kudenchuk PJ, Cobb LA, Copass MK, et al, &ldquo;Amiodarone for Resuscitation After Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(12):871-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/10486418/pubmed\" id=\"10486418\" target=\"_blank\">",
"        10486418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martino E, Bartalena L, Bogazzi, et al, &ldquo;The Effects of Amiondarone on the Thyroid,&rdquo;",
"      <i>",
"       Endocr Rev",
"      </i>",
"      , 2001, 22(2):240-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/11294826/pubmed\" id=\"11294826\" target=\"_blank\">",
"        11294826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massie BM, Fisher SG, Radford M, et al, &ldquo;Effect of Amiodarone on Clinical Status and Left Ventricular Function in Patients With Congestive Heart Failure. CHF-STAT Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1996, 93(12):2128-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/8925581/pubmed\" id=\"8925581\" target=\"_blank\">",
"        8925581",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKee MR, &ldquo;Amiodarone - An &ldquo;Old&rdquo; Drug With New Recommendations,&rdquo;",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 2003, 15(2):193-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/12640278/pubmed\" id=\"12640278\" target=\"_blank\">",
"        12640278",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Munoz A, Karila P, Gallay P, et al, &ldquo;A Randomized Hemodynamic Comparison of Intravenous Amiodarone With and Without Tween 80,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1988, 9(2):142-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/3280316/pubmed\" id=\"3280316\" target=\"_blank\">",
"        3280316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ott MC, Khoor A, Leventhal JP, et al, &ldquo;Pulmonary Toxicity in Patients Receiving Low-Dose Amiodarone,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(2):646-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/12576397/pubmed\" id=\"12576397\" target=\"_blank\">",
"        12576397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paul T and Guccione P, &ldquo;New Antiarrhythmic Drugs in Pediatric Use: Amiodarone,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1994, 15(3):132-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/8047495/pubmed\" id=\"8047495\" target=\"_blank\">",
"        8047495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paul T, Bertram H, Bokenkamp R, et al, &ldquo;Supraventricular Tachycardia in Infants, Children and Adolescents: Diagnosis, and Pharmacological and Interventional Therapy,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(3):171-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/10937468/pubmed\" id=\"10937468\" target=\"_blank\">",
"        10937468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry JC, Fenrich AL, Hulse JE, et al, &ldquo;Pediatric Use of Intravenous Amiodarone: Efficacy and Safety in Critically Ill Patients From a Multicenter Protocol,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1996, 27(5):1246-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/8609351/pubmed\" id=\"8609351\" target=\"_blank\">",
"        8609351",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raja P, Hawker RE, Chaikitpinyo A, et al, &ldquo;Amiodarone Management of Junctional Ectopic Tachycardia After Cardiac Surgery in Children,&rdquo;",
"      <i>",
"       Br Heart J",
"      </i>",
"      , 1994, 72(3):261-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/7946778/pubmed\" id=\"7946778\" target=\"_blank\">",
"        7946778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reiffel JA and Kowey PR,  \"Generic Antiarrhythmics Are not Therapeutically Equivalent for the Treatment of Tachyarrhythmias,\"",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2000, 85(9):1151-3, A10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/10781771/pubmed\" id=\"10781771\" target=\"_blank\">",
"        10781771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roy D, Talajic M, Dorian P, et al, &ldquo;Amiodarone to Prevent Recurrence of Atrial Fibrillation. Canadian Trial of Atrial Fibrillation Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(13):913-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/10738049/pubmed\" id=\"10738049\" target=\"_blank\">",
"        10738049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sauro SC, DeCarolis DD, Pierpont GL, et al, \"Comparison of Plasma Concentrations for Two Amiodarone Products,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1682-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/12398559/pubmed\" id=\"12398559\" target=\"_blank\">",
"        12398559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shahar E, Barzilay Z, Frand M, et al, &ldquo;Amiodarone in Control of Sustained Tachyarrhythmias in Children With Wolff-Parkinson-White Syndrome,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1983, 72(6):813-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/6646922/pubmed\" id=\"6646922\" target=\"_blank\">",
"        6646922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shuler CO, Case CL, and Gillette PC, &ldquo;Efficacy and Safety of Amiodarone in Infants,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1993, 125(5 Pt 1):1430-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/8480599/pubmed\" id=\"8480599\" target=\"_blank\">",
"        8480599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh SN, Fletcher RD, Fisher SG, et al, &ldquo;Amiodarone in Patients With Congestive Heart Failure and Asymptomatic Ventricular Arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(2):77-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/7539890/pubmed\" id=\"7539890\" target=\"_blank\">",
"        7539890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skrifvars MB, Kuisma M, Boyd J, et al, &ldquo;The Use of Undiluted Amiodarone in the Management of Out-of Hospital Cardiac Arrest,&rdquo;",
"      <i>",
"       Acta Anaesthesiol Scand",
"      </i>",
"      , 2004, 48(5):582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/15101852/pubmed\" id=\"15101852\" target=\"_blank\">",
"        15101852",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soult JA, Munoz M, Lopez JD, et al, &ldquo;Efficacy and Safety of Intravenous Amiodarone for Short-Term Treatment of Paroxysmal Supraventricular Tachycardia in Children,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1995, 16(1):16-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/7753695/pubmed\" id=\"7753695\" target=\"_blank\">",
"        7753695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stamou SC, Hill PC, Sample GA, et al, &ldquo;Prevention of Atrial Fibrillation After Cardiac Surgery: The Significance of Postoperative Oral Amiodarone,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2001, 120(6):1936-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/11742925/pubmed\" id=\"11742925\" target=\"_blank\">",
"        11742925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trip MD, Wiersinga W, and Plomp TA, &ldquo;Incidence, Predictability, and Pathogenesis of Amiodarone-Induced Thyrotoxicosis and Hypothyroidism,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      1991, 91(5):507-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/1951413/pubmed\" id=\"1951413\" target=\"_blank\">",
"        1951413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vorperian VR, Havighurst TC, Miller S, et al, &ldquo;Adverse Effects of Low Dose Amiodarone: A Meta-analysis,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1997, 30(3):791-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/9283542/pubmed\" id=\"9283542\" target=\"_blank\">",
"        9283542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimetbaum P, &ldquo;Amiodarone for Atrial Fibrillation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(9):935-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/17329700/pubmed\" id=\"17329700\" target=\"_blank\">",
"        17329700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(5):247-346.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/58/23466/abstract-text/16949478 /pubmed\" id=\"16949478 \" target=\"_blank\">",
"        16949478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8595 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23466=[""].join("\n");
var outline_f22_58_23466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708616\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133629\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133630\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133682\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133634\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133657\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133635\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133636\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133637\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133598\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133581\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874279\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133603\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471286\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471287\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133689\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133602\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133678\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133691\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133680\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133607\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133585\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133676\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133590\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133624\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133593\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133610\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133642\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133611\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133612\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133609\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133595\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133599\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869363\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133584\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133606\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8595|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/35/27189?source=related_link\">",
"      Amiodarone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=related_link\">",
"      Amiodarone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_58_23467="Clin manif RT fibrosis";
var content_f22_58_23467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common clinical manifestations of radiation-induced fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tissues",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manifestations and symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin, subcutaneous tissue",
"       </td>",
"       <td>",
"        Induration, thickening, impaired cosmesis, loss of elasticity, shrinkage, limited joint mobility, lymphedema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung",
"       </td>",
"       <td>",
"        Restrictive pulmonary symptoms, dyspnea, impaired lung function, oxygen dependency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck",
"       </td>",
"       <td>",
"        Trismus, mucosal fibrosis, ulcerations, fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal tract",
"       </td>",
"       <td>",
"        Obstruction, dysphagia, ulceration, fistula, diarrhea, pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract",
"       </td>",
"       <td>",
"        Ureteral and urethral stenosis, bladder shrinkage, urgency, increased voiding frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female genital tract",
"       </td>",
"       <td>",
"        Loss of reproductive function, pain, rigidness, shortness and narrowness of vagina, dyspareunia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscles",
"       </td>",
"       <td>",
"        Muscle atrophy, muscle shortening, reduced mobility, decreased strength",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23467=[""].join("\n");
var outline_f22_58_23467=null;
var title_f22_58_23468="Dressings for dystrophic EB";
var content_f22_58_23468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dressings for dystrophic epidermolysis bullosa",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Brand",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Wear time",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Soft silicone primary dressings",
"       </td>",
"       <td>",
"        <p>",
"         Mepitel",
"        </p>",
"        Silflex",
"       </td>",
"       <td>",
"        Moist wound",
"       </td>",
"       <td>",
"        Silicone sensitivity",
"       </td>",
"       <td>",
"        Change every three to four days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Lipidocolloid primary dressings",
"       </td>",
"       <td>",
"        Urgotul",
"       </td>",
"       <td>",
"        Moist wounds, drier wounds, protection of vulnerable skin",
"       </td>",
"       <td>",
"        Where retention difficult",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Soft silicone foam dressings",
"       </td>",
"       <td>",
"        <p>",
"         Mepilex",
"        </p>",
"        <p>",
"         Mepilex Lite",
"        </p>",
"        Mepilex Transfer",
"       </td>",
"       <td>",
"        <p>",
"         Absorption of exudate",
"        </p>",
"        <p>",
"         Protection",
"        </p>",
"        <p>",
"         Lightly exuding wounds",
"        </p>",
"        Where conformability required &ndash; digits and axillae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Change every three to four days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Foam dressings",
"       </td>",
"       <td>",
"        <p>",
"         Alleyvn",
"        </p>",
"        Urgocell",
"       </td>",
"       <td>",
"        <p>",
"         Absorption",
"        </p>",
"        Protection",
"       </td>",
"       <td>",
"        May need to apply over primary dressings",
"       </td>",
"       <td>",
"        Change every three to four days",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Polymeric membrane",
"       </td>",
"       <td>",
"        PolyMem",
"       </td>",
"       <td>",
"        Where cleansing required",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        As determined by level of exudate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bordered dressings",
"       </td>",
"       <td>",
"        <p>",
"         Mepilex Border",
"        </p>",
"        <p>",
"         Mepilex Border Lite",
"        </p>",
"        Alleyvn Gentle Border",
"       </td>",
"       <td>",
"        <p>",
"         Isolated wounds",
"        </p>",
"        Dominant and mild recessive DEB",
"       </td>",
"       <td>",
"        Use silicone medical removers to avoid skin stripping",
"       </td>",
"       <td>",
"        Change every three to four days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Denyer JE. Wound management for children with epidermolysis bullosa. Dermatol Clin 2010; 28:257. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23468=[""].join("\n");
var outline_f22_58_23468=null;
var title_f22_58_23469="Medications associated with drug-induced Sweet syndrome";
var content_f22_58_23469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications associated with drug-induced Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td rowspan=\"6\">",
"        <strong>",
"         Antibiotics",
"        </strong>",
"       </td>",
"       <td>",
"        Minocycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrofurantoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norfloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ofloxacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinupristin/dalfopristin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Antiepileptics",
"        </strong>",
"       </td>",
"       <td>",
"        Carbemazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diazepam",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Antihuman immunodeficiency virus drugs",
"        </strong>",
"       </td>",
"       <td>",
"        Abacavir (synthetic carbocyclic nucleoside analogue)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Antihypertensives",
"        </strong>",
"       </td>",
"       <td>",
"        Hydralazine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Antineoplastics",
"        </strong>",
"       </td>",
"       <td>",
"        Bortezomib*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imatinib mesylate",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lenalidomide",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Antipsychotics",
"        </strong>",
"       </td>",
"       <td>",
"        Clozapine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Antithyroid hormone synthesis drugs",
"        </strong>",
"       </td>",
"       <td>",
"        Propylthiouracil",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Colony stimulating factors",
"        </strong>",
"       </td>",
"       <td>",
"        Granulocyte-colony stimulating factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulocyte-macrophage-colony stimulating factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pegfilgrastim",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Contraceptives",
"        </strong>",
"       </td>",
"       <td>",
"        Levonorgestrel/ethinyl estradiol (Triphasil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levonorgestrel-releasing intrauterine system (Mirena)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Diuretics",
"        </strong>",
"       </td>",
"       <td>",
"        Furosemide",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Nonsteroidal antiinflammatory agents",
"        </strong>",
"       </td>",
"       <td>",
"        Celecoxib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diclofenac",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Retinoids",
"        </strong>",
"       </td>",
"       <td>",
"        All-trans retinoic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13-cis-retinoic acid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The possibility of acyclovir-induced Sweet syndrome cannot be completely ruled out in a 13-year-old girl with systemic lupus erythematosus (that had been diagnosed&nbsp;three months earlier and was being treated with oral prednisolone and azathioprine) whose Sweet syndrome lesions appeared&nbsp;five days after beginning intravenous acyclovir treatment for a herpes zoster infection.",
"    <br>",
"     Photodistributed neutrophilic dermatosis with overlapping features of Sweet syndrome, acute generalized exanthematous pustulosis and sterile neutrophilic folliculitis with perifollicular vasculopathy developed in a patient who had received antidepressant (amoxapine and citalopram) and anxiolytic (perphenazine) therapy.",
"     <br>",
"      Additional reports have attributed Sweet syndrome to medications (minocycline, furosemide, and hydralazine); however, they did not fulfill the criteria proposed by Walker and Cohen for drug-induced Sweet syndrome.",
"      <div class=\"footnotes\">",
"       * This drug is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. It is indicated for the treatment of multiple myeloma patients.",
"       <br/>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       This drug is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukemia.",
"       <br/>",
"       &Delta; This drug is an amino-substituted analogue of thalidomide. It is an immunomodulatory agent with anti-angiogenic and antineoplastic properties. It is indicated for the treatment of: (1) multiple myeloma and (2) transfusion dependent anemia due to low-risk or intermediate-risk myelodysplastic syndromes.",
"       <br/>",
"       <span class=\"lozenge\">",
"        &loz;",
"       </span>",
"       This drug is a covalent conjugate of recombinant methionyl human granulocyte-colony stimulating factor (Filgrastim) and monomethoxypolyethylene.",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced from: Cohen PR. Sweet's syndrome - a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2:34. Copyright &copy; 2007 BioMed Central Ltd.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23469=[""].join("\n");
var outline_f22_58_23469=null;
var title_f22_58_23470="Elements of decision analysis";
var content_f22_58_23470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Decision analysis elements",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23470=[""].join("\n");
var outline_f22_58_23470=null;
var title_f22_58_23471="CT of temporal skull fracture";
var content_f22_58_23471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Temporal skull fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The same skull fracture in the left temporal region seen with bone windows in a slightly more caudad slice (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_58_23471=[""].join("\n");
var outline_f22_58_23471=null;
